{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,21]],"date-time":"2026-04-21T18:14:03Z","timestamp":1776795243526,"version":"3.51.2"},"reference-count":224,"publisher":"Bentham Science Publishers Ltd.","issue":"5","funder":[{"DOI":"10.13039\/501100008530","name":"Fundo Europeu de Desenvolvimento Regional","doi-asserted-by":"publisher","award":["CENTRO-01-0145-FEDER-030752-N2BD"],"award-info":[{"award-number":["CENTRO-01-0145-FEDER-030752-N2BD"]}],"id":[{"id":"10.13039\/501100008530","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001871","name":"Funda\u00e7\u00e3o para a Ci\u00eancia e a Tecnologia","doi-asserted-by":"publisher","award":["POCI-01-0145-FEDER-030478"],"award-info":[{"award-number":["POCI-01-0145-FEDER-030478"]}],"id":[{"id":"10.13039\/501100001871","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["eurekaselect.com"],"crossmark-restriction":true},"short-container-title":["CPD"],"published-print":{"date-parts":[[2020,3,20]]},"abstract":"<jats:sec><jats:title>Background:<\/jats:title><jats:p>Several natural compounds have demonstrated potential for the treatment of central nervous system disorders such as ischemic cerebrovascular disease, glioblastoma, neuropathic pain, neurodegenerative diseases, multiple sclerosis and migraine. This is due to their well-known antioxidant, anti-inflammatory, neuroprotective, anti-tumor, anti-ischemic and analgesic properties. Nevertheless, many of these molecules have poor aqueous solubility, low bioavailability and extensive gastrointestinal and\/or hepatic first-pass metabolism, leading to a quick elimination as well as low serum and tissue concentrations. Thus, the intranasal route emerged as a viable alternative to oral or parenteral administration, by enabling a direct transport into the brain through the olfactory and trigeminal nerves. With this approach, the blood-brain barrier is circumvented and peripheral exposure is reduced, thereby minimizing possible adverse effects.<\/jats:p><\/jats:sec><jats:sec><jats:title>Objective:<\/jats:title><jats:p>Herein, brain-targeting strategies for nose-to-brain delivery of natural compounds, including flavonoids, cannabinoids, essential oils and terpenes, will be reviewed and discussed. Brain and plasma pharmacokinetics of these molecules will be analyzed and related to their physicochemical characteristics and formulation properties.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion:<\/jats:title><jats:p>Natural compounds constitute relevant alternatives for the treatment of brain diseases but often require loading into nanocarrier systems to reach the central nervous system in sufficient concentrations. Future challenges lie in a deeper characterization of their therapeutic mechanisms and in the development of effective, safe and brain-targeted delivery systems for their intranasal administration<\/jats:p><\/jats:sec>","DOI":"10.2174\/1381612826666200115101544","type":"journal-article","created":{"date-parts":[[2020,1,15]],"date-time":"2020-01-15T15:17:53Z","timestamp":1579101473000},"page":"594-619","update-policy":"https:\/\/doi.org\/10.2174\/bsp_crossmark_policy","source":"Crossref","is-referenced-by-count":29,"title":["Nose-to-brain Delivery of Natural Compounds for the Treatment of Central Nervous System Disorders"],"prefix":"10.2174","volume":"26","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7500-1671","authenticated-orcid":true,"given":"Joana","family":"Bicker","sequence":"first","affiliation":[{"name":"Laboratory of Pharmacology, Faculty of Pharmacy, University of Coimbra, Polo das Ciencias da Saude, Azinhaga de Santa Comba, 3000-548 Coimbra, Portugal"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6981-6639","authenticated-orcid":true,"given":"Ana","family":"Fortuna","sequence":"additional","affiliation":[{"name":"Laboratory of Pharmacology, Faculty of Pharmacy, University of Coimbra, Polo das Ciencias da Saude, Azinhaga de Santa Comba, 3000-548 Coimbra, Portugal"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4213-0714","authenticated-orcid":true,"given":"Gilberto","family":"Alves","sequence":"additional","affiliation":[{"name":"CICS-UBI - Health Sciences Research Centre, University of Beira Interior, Av. Infante D. Henrique, 6200-506 Covilha, Portugal"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3854-6549","authenticated-orcid":true,"given":"Am\u00edlcar","family":"Falc\u00e3o","sequence":"additional","affiliation":[{"name":"Laboratory of Pharmacology, Faculty of Pharmacy, University of Coimbra, Polo das Ciencias da Saude, Azinhaga de Santa Comba, 3000-548 Coimbra, Portugal"}]}],"member":"965","reference":[{"key":"ref=1","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1038\/nrn1824","volume":"7","author":"Abbott N.J.","year":"2006","unstructured":"Abbott N.J.; R\u00f6nnb\u00e4ck L.; Hansson E.; Astrocyte-endothelial interactions at the blood-brain barrier. Nat Rev Neurosci 2006,7(1),41-53","journal-title":"Nat Rev Neurosci"},{"key":"ref=2","doi-asserted-by":"publisher","first-page":"437","DOI":"10.1007\/s10545-013-9608-0","volume":"36","author":"Abbott N.J.","year":"2013","unstructured":"Abbott N.J.; Blood-brain barrier structure and function and the challenges for CNS drug delivery. J Inherit Metab Dis 2013,36(3),437-449","journal-title":"J Inherit Metab Dis"},{"key":"ref=3","doi-asserted-by":"publisher","first-page":"387","DOI":"10.1007\/s00401-018-1812-4","volume":"135","author":"Abbott N.J.","year":"2018","unstructured":"Abbott N.J.; Pizzo M.E.; Preston J.E.; Janigro D.; Thorne R.G.; The role of brain barriers in fluid movement in the CNS: is there a \u2018glymphatic\u2019 system? Acta Neuropathol 2018,135(3),387-407","journal-title":"Acta Neuropathol"},{"key":"ref=4","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1016\/j.nbd.2009.07.030","volume":"37","author":"Abbott N.J.","year":"2010","unstructured":"Abbott N.J.; Patabendige A.A.K.; Dolman D.E.M.; Yusof S.R.; Begley D.J.; Structure and function of the blood-brain barrier. Neurobiol Dis 2010,37(1),13-25","journal-title":"Neurobiol Dis"},{"key":"ref=5","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1007\/s40263-016-0405-9","volume":"31","author":"Patel M.M.","year":"2017","unstructured":"Patel M.M.; Patel B.M.; Crossing the blood-brain barrier: recent advances in drug delivery to the brain. CNS Drugs 2017,31(2),109-133","journal-title":"CNS Drugs"},{"key":"ref=6","doi-asserted-by":"publisher","first-page":"166","DOI":"10.1208\/s12248-008-9018-7","volume":"10","author":"Bellavance M.A.","year":"2008","unstructured":"Bellavance M.A.; Blanchette M.; Fortin D.; Recent advances in blood-brain barrier disruption as a CNS delivery strategy. AAPS J 2008,10(1),166-177","journal-title":"AAPS J"},{"key":"ref=7","doi-asserted-by":"publisher","first-page":"1177","DOI":"10.2174\/1381612822666151221150733","volume":"22","author":"Hersh D.S.","year":"2016","unstructured":"Hersh D.S.; Wadajkar A.S.; Roberts N.; Evolving drug delivery strategies to overcome the blood brain barrier. Curr Pharm Des 2016,22(9),1177-1193","journal-title":"Curr Pharm Des"},{"key":"ref=8","doi-asserted-by":"publisher","first-page":"46689","DOI":"10.1038\/srep46689","volume":"7","author":"Wu S.K.","year":"2017","unstructured":"Wu S.K.; Chu P.C.; Chai W.Y.; Characterization of different microbubbles in assisting focused ultrasound-induced blood-brain barrier opening. Sci Rep 2017,7,46689","journal-title":"Sci Rep"},{"key":"ref=9","doi-asserted-by":"publisher","first-page":"3743","DOI":"10.2147\/IJN.S193258","volume":"14","author":"Ha S.W.","year":"2019","unstructured":"Ha S.W.; Hwang K.; Jin J.; Ultrasound-sensitizing nanoparticle complex for overcoming the blood-brain barrier: an effective drug delivery system. Int J Nanomedicine 2019,14,3743-3752","journal-title":"Int J Nanomedicine"},{"key":"ref=10","doi-asserted-by":"publisher","first-page":"2104","DOI":"10.1016\/j.ultrasmedbio.2019.04.010","volume":"45","author":"Peng C.","year":"2019","unstructured":"Peng C.; Sun T.; Vykhodtseva N.; Intracranial nonthermal ablation mediated by transcranial focused ultrasound and phase-shift nanoemulsions. Ultrasound Med Biol 2019,45(8),2104-2117","journal-title":"Ultrasound Med Biol"},{"key":"ref=11","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1080\/17425247.2019.1583205","volume":"16","author":"Moura R.P.","year":"2019","unstructured":"Moura R.P.; Martins C.; Pinto S.; Sousa F.; Sarmento B.; Blood-brain barrier receptors and transporters: an insight on their function and how to exploit them through nanotechnology. Expert Opin Drug Deliv 2019,16(3),271-285","journal-title":"Expert Opin Drug Deliv"},{"key":"ref=12","doi-asserted-by":"publisher","DOI":"10.1007\/s11481-019-09875-w","author":"Shahjin F.","unstructured":"Shahjin F.; Chand S.; Yelamanchili S.V.; Extracellular vesicles as drug delivery vehicles to the central nervous system. J Neuroimmune Pharmacol 2019. In Press","journal-title":"J Neuroimmune Pharmacol"},{"key":"ref=13","doi-asserted-by":"publisher","first-page":"247","DOI":"10.1016\/j.jconrel.2017.07.001","volume":"262","author":"Rufino-Ramos D.","year":"2017","unstructured":"Rufino-Ramos D.; Albuquerque P.R.; Carmona V.; Perfeito R.; Nobre R.J.; Pereira de Almeida L.; Extracellular vesicles: novel promising delivery systems for therapy of brain diseases. J Control Release 2017,262,247-258","journal-title":"J Control Release"},{"key":"ref=14","doi-asserted-by":"publisher","first-page":"963","DOI":"10.1517\/17425247.2016.1171315","volume":"13","author":"Pardridge W.M.","year":"2016","unstructured":"Pardridge W.M.; CSF, blood-brain barrier, and brain drug delivery. Expert Opin Drug Deliv 2016,13(7),963-975","journal-title":"Expert Opin Drug Deliv"},{"key":"ref=15","doi-asserted-by":"publisher","first-page":"1737","DOI":"10.1007\/s11095-007-9502-2","volume":"25","author":"Hammarlund-Udenaes M.","year":"2008","unstructured":"Hammarlund-Udenaes M.; Frid\u00e9n M.; Syv\u00e4nen S.; Gupta A.; On the rate and extent of drug delivery to the brain. Pharm Res 2008,25(8),1737-1750","journal-title":"Pharm Res"},{"key":"ref=16","doi-asserted-by":"publisher","first-page":"445","DOI":"10.1113\/JP275105","volume":"596","author":"Pizzo M.E.","year":"2018","unstructured":"Pizzo M.E.; Wolak D.J.; Kumar N.N.; Intrathecal antibody distribution in the rat brain: surface diffusion, perivascular transport and osmotic enhancement of delivery. J Physiol 2018,596(3),445-475","journal-title":"J Physiol"},{"key":"ref=17","first-page":"191","author":"Serralheiro A.","year":"2013","unstructured":"Serralheiro A.; Alves G.; Sousa J.; Fortuna A.; Falc\u00e3o A.; Nose as a route for drug delivery 2013,191-215","journal-title":"Nose as a route for drug delivery"},{"key":"ref=18","doi-asserted-by":"publisher","first-page":"433","DOI":"10.1615\/CritRevTherDrugCarrierSyst.2018024697","volume":"35","author":"Fan Y.","year":"2018","unstructured":"Fan Y.; Chen M.; Zhang J.; Maincent P.; Xia X.; Wu W.; Updated progress of nanocarrier-based intranasal drug delivery systems for treatment of brain diseases. Crit Rev Ther Drug Carrier Syst 2018,35(5),433-467","journal-title":"Crit Rev Ther Drug Carrier Syst"},{"key":"ref=19","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1016\/j.ejpb.2014.03.004","volume":"88","author":"Fortuna A.","year":"2014","unstructured":"Fortuna A.; Alves G.; Serralheiro A.; Sousa J.; Falc\u00e3o A.; Intranasal delivery of systemic-acting drugs: small-molecules and biomacromolecules. Eur J Pharm Biopharm 2014,88(1),8-27","journal-title":"Eur J Pharm Biopharm"},{"key":"ref=20","doi-asserted-by":"publisher","first-page":"168","DOI":"10.1016\/j.fitote.2009.01.003","volume":"80","author":"Guo J.","year":"2009","unstructured":"Guo J.; Duan J.A.; Shang E.X.; Tang Y.; Qian D.; Determination of ligustilide in rat brain after nasal administration of essential oil from Rhizoma Chuanxiong. Fitoterapia 2009,80(3),168-172","journal-title":"Fitoterapia"},{"key":"ref=21","doi-asserted-by":"publisher","first-page":"1686","DOI":"10.1080\/03639045.2017.1338721","volume":"43","author":"Ahirrao M.","year":"2017","unstructured":"Ahirrao M.; Shrotriya S.; In vitro and in vivo evaluation of cubosomal in situ nasal gel containing resveratrol for brain targeting. Drug Dev Ind Pharm 2017,43(10),1686-1693","journal-title":"Drug Dev Ind Pharm"},{"key":"ref=22","doi-asserted-by":"publisher","first-page":"2584","DOI":"10.1021\/jm501535r","volume":"58","author":"Rankovic Z.","year":"2015","unstructured":"Rankovic Z.; CNS drug design: balancing physicochemical properties for optimal brain exposure. J Med Chem 2015,58(6),2584-2608","journal-title":"J Med Chem"},{"key":"ref=23","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1021\/jm301297f","volume":"56","author":"Di L.","year":"2013","unstructured":"Di L.; Rong H.; Feng B.; Demystifying brain penetration in central nervous system drug discovery. Miniperspective. J Med Chem 2013,56(1),2-12","journal-title":"J Med Chem"},{"key":"ref=24","doi-asserted-by":"publisher","first-page":"7559","DOI":"10.1021\/jm060642i","volume":"49","author":"Hitchcock S.A.","year":"2006","unstructured":"Hitchcock S.A.; Pennington L.D.; Structure-brain exposure relationships. J Med Chem 2006,49(26),7559-7583","journal-title":"J Med Chem"},{"key":"ref=25","doi-asserted-by":"publisher","first-page":"151","DOI":"10.3109\/10611869808997889","volume":"6","author":"van de Waterbeemd H.","year":"1998","unstructured":"van de Waterbeemd H.; Camenisch G.; Folkers G.; Chretien J.R.; Raevsky O.A.; Estimation of blood-brain barrier crossing of drugs using molecular size and shape, and H-bonding descriptors. J Drug Target 1998,6(2),151-165","journal-title":"J Drug Target"},{"key":"ref=26","doi-asserted-by":"publisher","first-page":"420","DOI":"10.1021\/cn100007x","volume":"1","author":"Wager T.T.","year":"2010","unstructured":"Wager T.T.; Chandrasekaran R.Y.; Hou X.; Defining desirable central nervous system drug space through the alignment of molecular properties, in vitro ADME, and safety attributes. ACS Chem Neurosci 2010,1(6),420-434","journal-title":"ACS Chem Neurosci"},{"key":"ref=27","author":"Yao Y.","year":"2017","unstructured":"Yao Y.; Chen T.; Huang J.; Zhang H.; Tian M.; Effect of chinese herbal medicine on molecular imaging of neurological disorders Int Rev Neurobiol 2017","journal-title":"Effect of chinese herbal medicine on molecular imaging of neurological disorders Int Rev Neurobiol"},{"key":"ref=28","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3390\/brainsci8060104","volume":"8","author":"Sowndhararajan K.","year":"2018","unstructured":"Sowndhararajan K.; Deepa P.; Kim M.; Park S.J.; Kim S.; Neuroprotective and cognitive enhancement potentials of baicalin: a review. Brain Sci 2018,8(6),1-24","journal-title":"Brain Sci"},{"key":"ref=29","first-page":"374","volume":"66","author":"Li N.","year":"2011","unstructured":"Li N.; Je Y.J.; Yang M.; Jiang X.H.; Ma J.H.; Pharmacokinetics of baicalin-phospholipid complex in rat plasma and brain tissues after intranasal and intravenous administration. Pharmazie 2011,66(5),374-377","journal-title":"Pharmazie"},{"key":"ref=30","doi-asserted-by":"publisher","first-page":"1495","DOI":"10.1111\/jphp.12797","volume":"69","author":"Liu S.","year":"2017","unstructured":"Liu S.; Ho P.C.; Intranasal administration of brain-targeted HP-\u03b2-CD\/chitosan nanoparticles for delivery of scutellarin, a compound with protective effect in cerebral ischaemia. J Pharm Pharmacol 2017,69(11),1495-1501","journal-title":"J Pharm Pharmacol"},{"key":"ref=31","doi-asserted-by":"publisher","first-page":"2844","DOI":"10.1016\/j.bmcl.2009.03.109","volume":"19","author":"Waring M.J.","year":"2009","unstructured":"Waring M.J.; Defining optimum lipophilicity and molecular weight ranges for drug candidates-molecular weight dependent lower logD limits based on permeability. Bioorg Med Chem Lett 2009,19(10),2844-2851","journal-title":"Bioorg Med Chem Lett"},{"key":"ref=32","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1016\/S0378-5173(03)00407-1","volume":"265","author":"Sasaki K.","year":"2003","unstructured":"Sasaki K.; Yonebayashi S.; Yoshida M.; Shimizu K.; Aotsuka T.; Takayama K.; Improvement in the bioavailability of poorly absorbed glycyrrhizin via various non-vascular administration routes in rats. Int J Pharm 2003,265(1-2),95-102","journal-title":"Int J Pharm"},{"key":"ref=33","doi-asserted-by":"publisher","first-page":"475","DOI":"10.1080\/21691401.2018.1561458","volume":"47","author":"Ahmad N.","year":"2019","unstructured":"Ahmad N.; Al-Subaiec A.M.; Ahmad R.; Brain-targeted glycyrrhizic-acid-loaded surface decorated nanoparticles for treatment of cerebral ischaemia and its toxicity assessment. Artif Cells Nanomed Biotechnol 2019,47(1),475-490","journal-title":"Artif Cells Nanomed Biotechnol"},{"key":"ref=34","doi-asserted-by":"publisher","first-page":"274","DOI":"10.1016\/S1875-5364(15)30014-5","volume":"13","author":"Bobade V.","year":"2015","unstructured":"Bobade V.; Bodhankar S.L.; Aswar U.; Vishwaraman M.; Thakurdesai P.; Prophylactic effects of asiaticoside-based standardized extract of Centella asiatica (L.) Urban leaves on experimental migraine: involvement of 5HT1A\/1B receptors. Chin J Nat Med 2015,13(4),274-282","journal-title":"Chin J Nat Med"},{"key":"ref=35","doi-asserted-by":"publisher","first-page":"264","DOI":"10.1016\/j.jchromb.2014.08.034","volume":"969","author":"Guo Q.","year":"2014","unstructured":"Guo Q.; Li P.; Wang Z.; Brain distribution pharmacokinetics and integrated pharmacokinetics of panax notoginsenoside R1, Ginsenosides Rg1, Rb1, Re and Rd in rats after intranasal administration of panax notoginseng saponins assessed by UPLC\/MS\/MS. J Chromatogr B Analyt Technol Biomed Life Sci 2014,969,264-271","journal-title":"J Chromatogr B Analyt Technol Biomed Life Sci"},{"key":"ref=36","doi-asserted-by":"publisher","first-page":"541","DOI":"10.1602\/neurorx.2.4.541","volume":"2","author":"Pajouhesh H.","year":"2005","unstructured":"Pajouhesh H.; Lenz G.R.; Medicinal chemical properties of successful central nervous system drugs. NeuroRx 2005,2(4),541-553","journal-title":"NeuroRx"},{"key":"ref=37","doi-asserted-by":"publisher","first-page":"218","DOI":"10.3389\/fnagi.2014.00218","volume":"6","author":"Rege S.D.","year":"2014","unstructured":"Rege S.D.; Geetha T.; Griffin G.D.; Broderick T.L.; Babu J.R.; Neuroprotective effects of resveratrol in Alzheimer disease pathology. Front Aging Neurosci 2014,6,218","journal-title":"Front Aging Neurosci"},{"key":"ref=38","doi-asserted-by":"publisher","first-page":"1261","DOI":"10.3389\/fphar.2018.01261","volume":"9","author":"Andrade S.","year":"2018","unstructured":"Andrade S.; Ramalho M.J.; Pereira M.D.C.; Loureiro J.A.; Resveratrol brain delivery for neurological disorders prevention and treatment. Front Pharmacol 2018,9,1261","journal-title":"Front Pharmacol"},{"key":"ref=39","doi-asserted-by":"publisher","first-page":"1359","DOI":"10.15252\/emmm.201302627","volume":"6","author":"Carlsson S.K.","year":"2014","unstructured":"Carlsson S.K.; Brothers S.P.; Wahlestedt C.; Emerging treatment strategies for glioblastoma multiforme. EMBO Mol Med 2014,6(11),1359-1370","journal-title":"EMBO Mol Med"},{"key":"ref=40","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1016\/j.canlet.2018.04.039","volume":"428","author":"Basso J.","year":"2018","unstructured":"Basso J.; Miranda A.; Sousa J.; Pais A.; Vitorino C.; Repurposing drugs for glioblastoma: From bench to bedside. Cancer Lett 2018,428,173-183","journal-title":"Cancer Lett"},{"key":"ref=41","doi-asserted-by":"publisher","DOI":"10.1155\/2017\/9363040","volume":"2017","author":"Desai V.","year":"2017","unstructured":"Desai V.; Bhushan A.; Natural bioactive compounds: alternative approach to the treatment of glioblastoma multiforme. BioMed Res Int 2017,2017","journal-title":"BioMed Res Int"},{"key":"ref=42","doi-asserted-by":"publisher","first-page":"2191","DOI":"10.1002\/ptr.6170","volume":"32","author":"Erices J.I.","year":"2018","unstructured":"Erices J.I.; Torres \u00c1.; Niechi I.; Bernales I.; Quezada C.; Current natural therapies in the treatment against glioblastoma. Phytother Res 2018,32(11),2191-2201","journal-title":"Phytother Res"},{"key":"ref=43","doi-asserted-by":"publisher","DOI":"10.1155\/2017\/8139848","volume":"2017","author":"Park M.N.","year":"2017","unstructured":"Park M.N.; Song H.S.; Kim M.; Review of natural product-derived compounds as potent antiglioblastoma drugs. BioMed Res Int 2017,2017","journal-title":"BioMed Res Int"},{"key":"ref=44","doi-asserted-by":"publisher","first-page":"22194","DOI":"10.18632\/oncotarget.25175","volume":"9","author":"Vengoji R.","year":"2018","unstructured":"Vengoji R.; Macha M.A.; Batra S.K.; Shonka N.A.; Natural products: a hope for glioblastoma patients. Oncotarget 2018,9(31),22194-22219","journal-title":"Oncotarget"},{"key":"ref=45","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3390\/ijms19020395","volume":"19","author":"Fan H.C.","year":"2018","unstructured":"Fan H.C.; Chi C.S.; Chang Y.K.; Tung M.C.; Lin S.Z.; Harn H.J.; The molecular mechanisms of plant-derived compounds targeting brain cancer. Int J Mol Sci 2018,19(2),1-15","journal-title":"Int J Mol Sci"},{"key":"ref=46","doi-asserted-by":"publisher","first-page":"30388","DOI":"10.1016\/j.drudis.2019.10.005","volume":"6446","author":"Sabir F.","year":"2019","unstructured":"Sabir F.; Ismail R.; Csoka I.; Nose-to-brain delivery of antiglioblastoma drugs embedded into lipid nanocarrier systems: status quo and outlook. Drug Discov Today 2019,6446(19),30388-5","journal-title":"Drug Discov Today"},{"key":"ref=47","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3390\/molecules24234312","volume":"24","author":"Bruinsmann F.A.","year":"2019","unstructured":"Bruinsmann F.A.; Richter Vaz G.; de Cristo Soares Alves A.; Nasal drug delivery of anticancer drugs for the treatment of glioblastoma: preclinical and clinical trials. Molecules 2019,24(23),1-32","journal-title":"Molecules"},{"key":"ref=48","doi-asserted-by":"publisher","first-page":"1565","DOI":"10.1111\/jphp.12781","volume":"69","author":"Zheng Y.","year":"2017","unstructured":"Zheng Y.; Liu H.; Liang Y.; Genistein exerts potent antitumour effects alongside anaesthetic, propofol, by suppressing cell proliferation and nuclear factor-\u03baB-mediated signalling and through upregulating microRNA-218 expression in an intracranial rat brain tumour model. J Pharm Pharmacol 2017,69(11),1565-1577","journal-title":"J Pharm Pharmacol"},{"key":"ref=49","doi-asserted-by":"publisher","first-page":"30042","DOI":"10.1016\/j.bbi.2019.05.003","volume":"1591","author":"da Silva AB","year":"2019","unstructured":"da Silva AB; Cerqueira Coelho PL; das Neves Oliveira M, et al. The flavonoid rutin and its aglycone quercetin modulate the microglia inflammatory profile improving antiglioma activity. Brain Behav Immun 2019,1591(19),30042","journal-title":"Brain Behav Immun"},{"key":"ref=50","volume":"2014","author":"Yang S.H.","year":"2014","unstructured":"Yang S.H.; Wang S.M.; Syu J.P.; Andrographolide induces apoptosis of C6 glioma cells via the ERK-p53-caspase 7-PARP pathway. BioMed Res Int 2014,2014","journal-title":"BioMed Res Int"},{"key":"ref=51","doi-asserted-by":"publisher","first-page":"105860","DOI":"10.18632\/oncotarget.22407","volume":"8","author":"Yang S.L.","year":"2017","unstructured":"Yang S.L.; Kuo F.H.; Chen P.N.; Andrographolide suppresses the migratory ability of human glioblastoma multiforme cells by targeting ERK1\/2-mediated matrix metalloproteinase-2 expression. Oncotarget 2017,8(62),105860-105872","journal-title":"Oncotarget"},{"key":"ref=52","doi-asserted-by":"publisher","first-page":"962","DOI":"10.1016\/j.lfs.2012.04.044","volume":"90","author":"Li Y.","year":"2012","unstructured":"Li Y.; Zhang P.; Qiu F.; Inactivation of PI3K\/Akt signaling mediates proliferation inhibition and G2\/M phase arrest induced by andrographolide in human glioblastoma cells. Life Sci 2012,90(25-26),962-967","journal-title":"Life Sci"},{"key":"ref=53","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3390\/molecules22091516","volume":"22","author":"Hou J.","year":"2017","unstructured":"Hou J.; Kim S.; Sung C.; Choi C.; Ginsenoside Rg3 prevents oxidative stress-induced astrocytic senescence and ameliorates senescence paracrine effects on glioblastoma. Molecules 2017,22(9),1-14","journal-title":"Molecules"},{"key":"ref=54","doi-asserted-by":"publisher","first-page":"2838","DOI":"10.1002\/ijc.30398","volume":"139","author":"Mukherjee S.","year":"2016","unstructured":"Mukherjee S.; Baidoo J.; Fried A.; Curcumin changes the polarity of tumor-associated microglia and eliminates glioblastoma. Int J Cancer 2016,139(12),2838-2849","journal-title":"Int J Cancer"},{"key":"ref=55","doi-asserted-by":"publisher","first-page":"464","DOI":"10.4161\/cbt.11.5.14410","volume":"11","author":"Lim K.J.","year":"2011","unstructured":"Lim K.J.; Bisht S.; Bar E.E.; Maitra A.; Eberhart C.G.; A polymeric nanoparticle formulation of curcumin inhibits growth, clonogenicity and stem-like fraction in malignant brain tumors. Cancer Biol Ther 2011,11(5),464-473","journal-title":"Cancer Biol Ther"},{"key":"ref=56","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3390\/molecules23010201","volume":"23","author":"Mukherjee S.","year":"2018","unstructured":"Mukherjee S.; Baidoo J.N.E.; Sampat S.; Liposomal tricurin, a synergistic combination of curcumin, epicatechin gallate and resveratrol, repolarizes tumor-associated microglia\/macrophages, and eliminates glioblastoma (GBM) and GBM Stem Cells. Molecules 2018,23(1),1-21","journal-title":"Molecules"},{"key":"ref=57","doi-asserted-by":"publisher","first-page":"601","DOI":"10.1080\/1061186X.2018.1550647","volume":"27","author":"Jhaveri A.","year":"2019","unstructured":"Jhaveri A.; Luther E.; Torchilin V.; The effect of transferrin-targeted, resveratrol-loaded liposomes on neurosphere cultures of glioblastoma: implications for targeting tumour-initiating cells. J Drug Target 2019,27(5-6),601-613","journal-title":"J Drug Target"},{"key":"ref=58","doi-asserted-by":"publisher","first-page":"343","DOI":"10.3892\/or.2015.4346","volume":"35","author":"Li H.","year":"2016","unstructured":"Li H.; Liu Y.; Jiao Y.; Resveratrol sensitizes glioblastoma-initiating cells to temozolomide by inducing cell apoptosis and promoting differentiation. Oncol Rep 2016,35(1),343-351","journal-title":"Oncol Rep"},{"key":"ref=59","doi-asserted-by":"crossref","DOI":"10.1155\/2019\/4619865","volume":"2019","author":"\u00d6zt\u00fcrk Y.","year":"2019","unstructured":"\u00d6zt\u00fcrk Y.; G\u00fcnayd\u0131n C.; Yal\u00e7\u0131n F.; Naz\u0131ro\u011flu M.; Braidy N.; Resveratrol enhances apoptotic and oxidant effects of paclitaxel through TRPM2 channel activation in DBTRG glioblastoma cells. Oxid Med Cell Longev 2019,2019","journal-title":"Oxid Med Cell Longev"},{"key":"ref=60","doi-asserted-by":"publisher","first-page":"763","DOI":"10.1007\/s12192-019-01004-z","volume":"24","author":"\u00d6nay U\u00e7ar E.","year":"2019","unstructured":"\u00d6nay U\u00e7ar E.; \u015eengelen A.; Resveratrol and siRNA in combination reduces Hsp27 expression and induces caspase-3 activity in human glioblastoma cells. Cell Stress Chaperones 2019,24(4),763-775","journal-title":"Cell Stress Chaperones"},{"key":"ref=61","doi-asserted-by":"publisher","first-page":"832","DOI":"10.1038\/aps.2014.22","volume":"35","author":"Sang D.P.","year":"2014","unstructured":"Sang D.P.; Li R.J.; Lan Q.; Quercetin sensitizes human glioblastoma cells to temozolomide in vitro via inhibition of Hsp27. Acta Pharmacol Sin 2014,35(6),832-838","journal-title":"Acta Pharmacol Sin"},{"key":"ref=62","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1016\/j.biopha.2017.05.044","volume":"92","author":"Liu Y.","year":"2017","unstructured":"Liu Y.; Tang Z.G.; Lin Y.; Effects of quercetin on proliferation and migration of human glioblastoma U251 cells. Biomed Pharmacother 2017,92,33-38","journal-title":"Biomed Pharmacother"},{"key":"ref=63","doi-asserted-by":"publisher","first-page":"287","DOI":"10.1007\/s00432-010-0873-0","volume":"137","author":"da Fonseca C.O.","year":"2011","unstructured":"da Fonseca C.O.; Sim\u00e3o M.; Lins I.R.; Caetano R.O.; Futuro D.; Quirico-Santos T.; Efficacy of monoterpene perillyl alcohol upon survival rate of patients with recurrent glioblastoma. J Cancer Res Clin Oncol 2011,137(2),287-293","journal-title":"J Cancer Res Clin Oncol"},{"key":"ref=64","first-page":"1580","volume":"5","author":"Chen T.C.","year":"2015","unstructured":"Chen T.C.; Fonseca C.O.; Sch\u00f6nthal A.H.; Preclinical development and clinical use of perillyl alcohol for chemoprevention and cancer therapy. Am J Cancer Res 2015,5(5),1580-1593","journal-title":"Am J Cancer Res"},{"key":"ref=65","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3390\/ijms19123905","volume":"19","author":"Chen T.C.","year":"2018","unstructured":"Chen T.C.; da Fonseca C.O.; Sch\u00f6nthal A.H.; Intranasal perillyl alcohol for glioma therapy: molecular mechanisms and clinical development. Int J Mol Sci 2018,19(12),1-21","journal-title":"Int J Mol Sci"},{"key":"ref=66","doi-asserted-by":"publisher","first-page":"310","DOI":"10.1016\/j.neuropharm.2008.01.005","volume":"55","author":"Doyle K.P.","year":"2008","unstructured":"Doyle K.P.; Simon R.P.; Stenzel-Poore M.P.; Mechanisms of ischemic brain damage. Neuropharmacology 2008,55(3),310-318","journal-title":"Neuropharmacology"},{"key":"ref=67","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1186\/1750-1326-6-11","volume":"6","author":"Woodruff T.M.","year":"2011","unstructured":"Woodruff T.M.; Thundyil J.; Tang S.C.; Sobey C.G.; Taylor S.M.; Arumugam T.V.; Pathophysiology, treatment, and animal and cellular models of human ischemic stroke. Mol Neurodegener 2011,6(1),11","journal-title":"Mol Neurodegener"},{"key":"ref=68","doi-asserted-by":"publisher","first-page":"640","DOI":"10.1016\/j.ijbiomac.2016.06.001","volume":"91","author":"Ahmad N.","year":"2016","unstructured":"Ahmad N.; Ahmad R.; Naqvi A.A.; Rutin-encapsulated chitosan nanoparticles targeted to the brain in the treatment of cerebral ischemia. Int J Biol Macromol 2016,91,640-655","journal-title":"Int J Biol Macromol"},{"key":"ref=69","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1016\/S1570-0232(02)01032-2","volume":"788","author":"Li H.","year":"2003","unstructured":"Li H.; Wang H.; Chen J.H.; Wang L.H.; Zhang H.S.; Fan Y.; Determination of amino acid neurotransmitters in cerebral cortex of rats administered with baicalin prior to cerebral ischemia by capillary electrophoresis-laser-induced fluorescence detection. J Chromatogr B Analyt Technol Biomed Life Sci 2003,788(1),93-101","journal-title":"J Chromatogr B Analyt Technol Biomed Life Sci"},{"key":"ref=70","doi-asserted-by":"publisher","first-page":"1625","DOI":"10.4103\/1673-5374.217335","volume":"12","author":"Zhou Z.Q.","year":"2017","unstructured":"Zhou Z.Q.; Li Y.L.; Ao Z.B.; Baicalin protects neonatal rat brains against hypoxicischemic injury by upregulating glutamate transporter 1 via the phosphoinositide 3-kinase\/protein kinase B. Neural Regen Res 2017,12,1625-1631","journal-title":"Neural Regen Res"},{"key":"ref=71","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1016\/j.ijpharm.2015.04.049","volume":"489","author":"Liu Z.","year":"2015","unstructured":"Liu Z.; Zhang L.; He Q.; Effect of Baicalin-loaded PEGylated cationic solid lipid nanoparticles modified by OX26 antibody on regulating the levels of baicalin and amino acids during cerebral ischemia-reperfusion in rats. Int J Pharm 2015,489(1-2),131-138","journal-title":"Int J Pharm"},{"key":"ref=72","doi-asserted-by":"publisher","first-page":"515","DOI":"10.1007\/s12975-017-0598-3","volume":"9","author":"Chen H.","year":"2018","unstructured":"Chen H.; Guan B.; Chen X.; Baicalin attenuates blood-brain barrier disruption and hemorrhagic transformation and improves neurological outcome in ischemic stroke rats with delayed t-PA treatment: involvement of ONOO-MMP-9 pathway. Transl Stroke Res 2018,9(5),515-529","journal-title":"Transl Stroke Res"},{"key":"ref=73","doi-asserted-by":"publisher","first-page":"961","DOI":"10.1038\/aps.2017.145","volume":"39","author":"Wang P.Q.","year":"2018","unstructured":"Wang P.Q.; Liu Q.; Xu W.J.; Pure mechanistic analysis of additive neuroprotective effects between baicalin and jasminoidin in ischemic stroke mice. Acta Pharmacol Sin 2018,39(6),961-974","journal-title":"Acta Pharmacol Sin"},{"key":"ref=74","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejphar.2019.172484","volume":"859","author":"Wu J.","year":"2019","unstructured":"Wu J.; Wang B.; Li M.; Shi Y.H.; Wang C.; Kang Y.G.; Network pharmacology identification of mechanisms of cerebral ischemia injury amelioration by baicalin and geniposide. Eur J Pharmacol 2019,859","journal-title":"Eur J Pharmacol"},{"key":"ref=75","doi-asserted-by":"publisher","first-page":"320","DOI":"10.3892\/etm.2012.798","volume":"15","author":"Cheng F.","year":"2018","unstructured":"Cheng F.; Ma C.; Sun L.; Synergistic neuroprotective effects of Geniposide and ursodeoxycholic acid in hypoxia-reoxygenation injury in SH-SY5Y cells. Exp Ther Med 2018,15(1),320-326","journal-title":"Exp Ther Med"},{"key":"ref=76","first-page":"3186","volume":"17","author":"Wang J.","year":"2018","unstructured":"Wang J.; Li D.; Hou J.; Lei H.; Protective effects of geniposide and ginsenoside Rg1 combination treatment on rats following cerebral ischemia are mediated via microglial microRNA1555p inhibition. Mol Med Rep 2018,17(2),3186-3193","journal-title":"Mol Med Rep"},{"key":"ref=77","doi-asserted-by":"publisher","first-page":"235","DOI":"10.2174\/187152711794480456","volume":"10","author":"Tang B.","year":"2011","unstructured":"Tang B.; Qu Y.; Wang D.; Mu D.; Targeting hypoxia inducible factor-1\u03b1: a novel mechanism of ginsenoside Rg1 for brain repair after hypoxia\/ischemia brain damage. CNS Neurol Disord Drug Targets 2011,10(2),235-238","journal-title":"CNS Neurol Disord Drug Targets"},{"key":"ref=78","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1016\/j.lfs.2014.12.002","volume":"121","author":"Xie C.L.","year":"2015","unstructured":"Xie C.L.; Li J.H.; Wang W.W.; Zheng G.Q.; Wang L.X.; Neuroprotective effect of ginsenoside-Rg1 on cerebral ischemia\/reperfusion injury in rats by downregulating protease-activated receptor-1 expression. Life Sci 2015,121,145-151","journal-title":"Life Sci"},{"key":"ref=79","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1016\/j.ejphar.2019.02.018","volume":"853","author":"Zheng T.","year":"2019","unstructured":"Zheng T.; Jiang H.; Jin R.; Ginsenoside Rg1 attenuates protein aggregation and inflammatory response following cerebral ischemia and reperfusion injury. Eur J Pharmacol 2019,853,65-73","journal-title":"Eur J Pharmacol"},{"key":"ref=80","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejphar.2019.172418","volume":"856","author":"Chen J.","year":"2019","unstructured":"Chen J.; Zhang X.; Liu X.; Ginsenoside Rg1 promotes cerebral angiogenesis via the PI3K\/Akt\/mTOR signaling pathway in ischemic mice. Eur J Pharmacol 2019,856","journal-title":"Eur J Pharmacol"},{"key":"ref=81","doi-asserted-by":"publisher","first-page":"865","DOI":"10.1097\/00004647-200107000-00012","volume":"21","author":"Hu B.R.","year":"2001","unstructured":"Hu B.R.; Janelidze S.; Ginsberg M.D.; Protein aggregation after focal brain ischemia and reperfusion. J Cereb Blood Flow Metab 2001,21(7),865-875","journal-title":"J Cereb Blood Flow Metab"},{"key":"ref=82","doi-asserted-by":"publisher","first-page":"1789","DOI":"10.1177\/0963689718780930","volume":"27","author":"Yang J.","year":"2018","unstructured":"Yang J.; Huang J.; Shen C.; Resveratrol treatment in different time-attenuated neuronal apoptosis after oxygen and glucose deprivation\/reoxygenation via enhancing the activation of Nrf-2 signaling pathway in vitro. Cell Transplant 2018,27(12),1789-1797","journal-title":"Cell Transplant"},{"key":"ref=83","doi-asserted-by":"publisher","first-page":"440","DOI":"10.1080\/13880209.2018.1502326","volume":"56","author":"Gao Y.","year":"2018","unstructured":"Gao Y.; Fu R.; Wang J.; Yang X.; Wen L.; Feng J.; Resveratrol mitigates the oxidative stress mediated by hypoxic-ischemic brain injury in neonatal rats via Nrf2\/HO-1 pathway. Pharm Biol 2018,56(1),440-449","journal-title":"Pharm Biol"},{"key":"ref=84","doi-asserted-by":"publisher","first-page":"872","DOI":"10.1007\/s12031-014-0441-1","volume":"55","author":"Wei H.","year":"2015","unstructured":"Wei H.; Wang S.; Zhen L.; Resveratrol attenuates the blood-brain barrier dysfunction by regulation of the MMP-9\/TIMP-1 balance after cerebral ischemia reperfusion in rats. J Mol Neurosci 2015,55(4),872-879","journal-title":"J Mol Neurosci"},{"key":"ref=85","doi-asserted-by":"publisher","first-page":"499","DOI":"10.1242\/dmm.030205","volume":"10","author":"Gitler A.D.","year":"2017","unstructured":"Gitler A.D.; Dhillon P.; Shorter J.; Neurodegenerative disease: models, mechanisms, and a new hope. Dis Model Mech 2017,10(5),499-502","journal-title":"Dis Model Mech"},{"key":"ref=86","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1146\/annurev.pathol.1.110304.100113","volume":"1","author":"Skovronsky D.M.","year":"2006","unstructured":"Skovronsky D.M.; Lee V.M-Y.; Trojanowski J.Q.; Neurodegenerative diseases: new concepts of pathogenesis and their therapeutic implications. Annu Rev Pathol 2006,1,151-170","journal-title":"Annu Rev Pathol"},{"key":"ref=87","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1101\/cshperspect.a028035","volume":"9","author":"Dugger B.N.","year":"2017","unstructured":"Dugger B.N.; Dickson D.W.; Pathology of neurodegenerative diseases. Cold Spring Harb Perspect Biol 2017,9(7),1-22","journal-title":"Cold Spring Harb Perspect Biol"},{"key":"ref=88","doi-asserted-by":"publisher","first-page":"114","DOI":"10.3389\/fncel.2018.00114","volume":"12","author":"Solleiro-Villavicencio H.","year":"2018","unstructured":"Solleiro-Villavicencio H.; Rivas-Arancibia S.; Effect of chronic oxidative stress on neuroinflammatory response mediated by CD4+T cells in neurodegenerative diseases. Front Cell Neurosci 2018,12,114","journal-title":"Front Cell Neurosci"},{"key":"ref=89","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1111\/j.1527-3458.2002.tb00221.x","volume":"8","author":"Lilienfeld S.","year":"2002","unstructured":"Lilienfeld S.; Galantamine-a novel cholinergic drug with a unique dual mode of action for the treatment of patients with Alzheimer\u2019s disease. CNS Drug Rev 2002,8(2),159-176","journal-title":"CNS Drug Rev"},{"key":"ref=90","doi-asserted-by":"publisher","first-page":"301","DOI":"10.1208\/s12249-019-1513-x","volume":"20","author":"Chen Y.","year":"2019","unstructured":"Chen Y.; Cheng G.; Hu R.; A nasal temperature and pH dual-responsive in situ gel delivery system based on microemulsion of huperzine a: formulation, evaluation, and in vivo pharmacokinetic study. AAPS PharmSciTech 2019,20(7),301","journal-title":"AAPS PharmSciTech"},{"key":"ref=91","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0074916","volume":"8","author":"Yang G.","year":"2013","unstructured":"Yang G.; Wang Y.; Tian J.; Liu J.P.; Huperzine a for alzheimer\u2019s disease: a systematic review and meta-analysis of randomized clinical trials. PLoS One 2013,8(9)","journal-title":"PLoS One"},{"key":"ref=92","doi-asserted-by":"publisher","first-page":"705","DOI":"10.2147\/IJN.S151474","volume":"13","author":"Meng Q.","year":"2018","unstructured":"Meng Q.; Wang A.; Hua H.; Intranasal delivery of Huperzine a to the brain using lactoferrin-conjugated N-trimethylated chitosan surface-modified PLGA nanoparticles for treatment of Alzheimer\u2019s disease. Int J Nanomedicine 2018,13,705-718","journal-title":"Int J Nanomedicine"},{"key":"ref=93","doi-asserted-by":"publisher","DOI":"10.1016\/j.fct.2017.06.005","author":"Li J","year":"Food Chem Toxicol 2017; 107(Pt. A): 68-73","unstructured":"Li J; Yue M; Zhou D; Wang M; Zhang H.; Abcb1a but not Abcg2 played a predominant role in limiting the brain distribution of Huperzine A in mice Food Chem Toxicol 2017; 107(Pt. A): 68-73","journal-title":"Abcb1a but not Abcg2 played a predominant role in limiting the brain distribution of Huperzine A in mice"},{"key":"ref=94","doi-asserted-by":"publisher","first-page":"354","DOI":"10.1080\/00498254.2019.1623935","volume":"50","author":"Fei Z.","year":"2019","unstructured":"Fei Z.; Hu M.; Baum L.; Kwan P.; Hong T.; Zhang C.; The potential role of human multidrug resistance protein 1 (MDR1) and multidrug resistance-associated protein 2 (MRP2) in the transport of Huperzine A in vitro. Xenobiotica 2019,50(3),354-362","journal-title":"Xenobiotica"},{"key":"ref=95","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1016\/j.nbd.2011.07.005","volume":"44","author":"Gong E.J.","year":"2011","unstructured":"Gong E.J.; Park H.R.; Kim M.E.; Morin attenuates tau hyperphosphorylation by inhibiting GSK3\u03b2. Neurobiol Dis 2011,44(2),223-230","journal-title":"Neurobiol Dis"},{"key":"ref=96","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1515\/tnsci-2018-0010","volume":"9","author":"Yu K.C.","year":"2018","unstructured":"Yu K.C.; Kwan P.; Cheung S.K.K.; Ho A.; Baum L.; Effects of resveratrol and morin on insoluble tau in tau transgenic mice. Transl Neurosci 2018,9,54-60","journal-title":"Transl Neurosci"},{"key":"ref=97","doi-asserted-by":"publisher","first-page":"9626","DOI":"10.1021\/acs.jafc.7b03252","volume":"65","author":"Jhang K.A.","year":"2017","unstructured":"Jhang K.A.; Park J.S.; Kim H.S.; Chong Y.H.; Resveratrol ameliorates tau hyperphosphorylation at ser396 site and oxidative damage in rat hippocampal slices exposed to vanadate: implication of ERK1\/2 and GSK-3\u03b2 signaling cascades. J Agric Food Chem 2017,65(44),9626-9634","journal-title":"J Agric Food Chem"},{"key":"ref=98","doi-asserted-by":"publisher","first-page":"7481","DOI":"10.1039\/C9NR01255A","volume":"11","author":"Wang H.","year":"2019","unstructured":"Wang H.; Sui H.; Zheng Y.; Curcumin-primed exosomes potently ameliorate cognitive function in AD mice by inhibiting hyperphosphorylation of the Tau protein through the AKT\/GSK-3\u03b2 pathway. Nanoscale 2019,11(15),7481-7496","journal-title":"Nanoscale"},{"key":"ref=99","doi-asserted-by":"publisher","first-page":"999","DOI":"10.3233\/JAD-170351","volume":"60","author":"Rane J.S.","year":"2017","unstructured":"Rane J.S.; Bhaumik P.; Panda D.; Curcumin inhibits tau aggregation and disintegrates preformed tau filaments in vitro. J Alzheimers Dis 2017,60(3),999-1014","journal-title":"J Alzheimers Dis"},{"key":"ref=100","doi-asserted-by":"publisher","first-page":"5892","DOI":"10.1074\/jbc.M404751200","volume":"280","author":"Yang F.","year":"2005","unstructured":"Yang F.; Lim G.P.; Begum A.N.; Curcumin inhibits formation of amyloid \u03b2 oligomers and fibrils, binds plaques, and reduces amyloid in vivo. J Biol Chem 2005,280(7),5892-5901","journal-title":"J Biol Chem"},{"key":"ref=101","doi-asserted-by":"publisher","first-page":"5990","DOI":"10.1021\/bi300113x","volume":"51","author":"Lemkul J.A.","year":"2012","unstructured":"Lemkul J.A.; Bevan D.R.; Morin inhibits the early stages of amyloid \u03b2-peptide aggregation by altering tertiary and quaternary interactions to produce \u201coff-pathway\u201d structures. Biochemistry 2012,51(30),5990-6009","journal-title":"Biochemistry"},{"key":"ref=102","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3390\/nu9101122","volume":"9","author":"Jia Y.","year":"2017","unstructured":"Jia Y.; Wang N.; Liu X.; Resveratrol and amyloid-beta: mechanistic insights. Nutrients 2017,9(10),1-13","journal-title":"Nutrients"},{"key":"ref=103","doi-asserted-by":"publisher","first-page":"1444","DOI":"10.3109\/10717544.2015.1092619","volume":"23","author":"Nasr M.","year":"2016","unstructured":"Nasr M.; Development of an optimized hyaluronic acid-based lipidic nanoemulsion co-encapsulating two polyphenols for nose to brain delivery. Drug Deliv 2016,23(4),1444-1452","journal-title":"Drug Deliv"},{"key":"ref=104","doi-asserted-by":"publisher","first-page":"865","DOI":"10.1002\/jnr.23764","volume":"94","author":"Lee K.M.","year":"2016","unstructured":"Lee K.M.; Lee Y.; Chun H.J.; Neuroprotective and anti-inflammatory effects of morin in a murine model of Parkinson\u2019s disease. J Neurosci Res 2016,94(10),865-878","journal-title":"J Neurosci Res"},{"key":"ref=105","doi-asserted-by":"publisher","first-page":"1127","DOI":"10.2217\/nnm.14.165","volume":"10","author":"Lindner G da R.","year":"2015","unstructured":"Lindner G da R.; Santos D.B.; Colle D.; Moreira E.L.G.; Prediger R.D.; Farina M.; Improved neuroprotective effects of poly(lactide) nanoparticles in MPTP-induced Parkinsonism. Nanomedicine (Lond) 2015,10,1127-1138","journal-title":"Nanomedicine (Lond)"},{"key":"ref=106","doi-asserted-by":"publisher","first-page":"681","DOI":"10.1159\/000495326","volume":"51","author":"Sang Q.","year":"2018","unstructured":"Sang Q.; Liu X.; Wang L.; Curcumin protects an SH-SY5Y cell model of Parkinson\u2019s disease against toxic injury by regulating HSP90. Cell Physiol Biochem 2018,51(2),681-691","journal-title":"Cell Physiol Biochem"},{"key":"ref=107","doi-asserted-by":"publisher","first-page":"156","DOI":"10.1016\/j.neures.2007.10.005","volume":"60","author":"Liu L.X.","year":"2008","unstructured":"Liu L.X.; Chen W.F.; Xie J.X.; Wong M.S.; Neuroprotective effects of genistein on dopaminergic neurons in the mice model of Parkinson\u2019s disease. Neurosci Res 2008,60(2),156-161","journal-title":"Neurosci Res"},{"key":"ref=108","doi-asserted-by":"publisher","first-page":"349","DOI":"10.1007\/s10787-017-0402-8","volume":"26","author":"Sharma N.","year":"2018","unstructured":"Sharma N.; Nehru B.; Curcumin affords neuroprotection and inhibits \u03b1-synuclein aggregation in lipopolysaccharide-induced parkinson\u2019s disease model. Inflammopharmacology 2018,26(2),349-360","journal-title":"Inflammopharmacology"},{"key":"ref=109","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1016\/j.phymed.2018.09.207","volume":"52","author":"Langasco R.","year":"2019","unstructured":"Langasco R.; Fancello S.; Rassu G.; Increasing protective activity of genistein by loading into transfersomes: A new potential adjuvant in the oxidative stress-related neurodegenerative diseases? Phytomedicine 2019,52,23-31","journal-title":"Phytomedicine"},{"key":"ref=110","doi-asserted-by":"publisher","first-page":"1375","DOI":"10.4103\/1673-5374.235250","volume":"13","author":"Wu H.C.","year":"2018","unstructured":"Wu H.C.; Hu Q.L.; Zhang S.J.; Neuroprotective effects of genistein on SH-SY5Y cells overexpressing A53T mutant \u03b1-synuclein. Neural Regen Res 2018,13(8),1375-1383","journal-title":"Neural Regen Res"},{"key":"ref=111","doi-asserted-by":"publisher","first-page":"715","DOI":"10.1007\/s11011-019-00405-4","volume":"34","author":"Pierzynowska K.","year":"2019","unstructured":"Pierzynowska K.; Gaffke L.; Cyske Z.; W\u0119grzyn G.; Genistein induces degradation of mutant huntingtin in fibroblasts from Huntington\u2019s disease patients. Metab Brain Dis 2019,34(3),715-720","journal-title":"Metab Brain Dis"},{"key":"ref=112","doi-asserted-by":"publisher","first-page":"931","DOI":"10.3109\/10717544.2014.880860","volume":"22","author":"Bhatt R.","year":"2015","unstructured":"Bhatt R.; Singh D.; Prakash A.; Mishra N.; Development, characterization and nasal delivery of rosmarinic acid-loaded solid lipid nanoparticles for the effective management of Huntington\u2019s disease. Drug Deliv 2015,22(7),931-939","journal-title":"Drug Deliv"},{"key":"ref=113","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1016\/j.neubiorev.2018.03.011","volume":"88","author":"De Somma E.","year":"2018","unstructured":"De Somma E.; Jain R.W.; Poon K.W.C.; Tresidder K.A.; Segal J.P.; Ghasemlou N.; Chronobiological regulation of psychosocial and physiological outcomes in multiple sclerosis. Neurosci Biobehav Rev 2018,88,73-83","journal-title":"Neurosci Biobehav Rev"},{"key":"ref=114","doi-asserted-by":"publisher","first-page":"366","DOI":"10.1124\/jpet.104.072512","volume":"312","author":"Iruretagoyena M.I.","year":"2005","unstructured":"Iruretagoyena M.I.; Tobar J.A.; Gonz\u00e1lez P.A.; Andrographolide interferes with T cell activation and reduces experimental autoimmune encephalomyelitis in the mouse. J Pharmacol Exp Ther 2005,312(1),366-372","journal-title":"J Pharmacol Exp Ther"},{"key":"ref=115","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1186\/s12883-016-0595-2","volume":"16","author":"Bertoglio J.C.","year":"2016","unstructured":"Bertoglio J.C.; Baumgartner M.; Palma R.; Andrographis paniculata decreases fatigue in patients with relapsing-remitting multiple sclerosis: a 12-month double-blind placebo-controlled pilot study. BMC Neurol 2016,16,77","journal-title":"BMC Neurol"},{"key":"ref=116","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1016\/j.msard.2017.06.015","volume":"17","author":"Giacoppo S.","year":"2017","unstructured":"Giacoppo S.; Bramanti P.; Mazzon E.; Sativex in the management of multiple sclerosis-related spasticity: an overview of the last decade of clinical evaluation. Mult Scler Relat Disord 2017,17,22-31","journal-title":"Mult Scler Relat Disord"},{"key":"ref=117","doi-asserted-by":"publisher","first-page":"1386","DOI":"10.1177\/1352458516643600","volume":"22","author":"Otero-Romero S.","year":"2016","unstructured":"Otero-Romero S.; Sastre-Garriga J.; Comi G.; Pharmacological management of spasticity in multiple sclerosis: systematic review and consensus paper. Mult Scler 2016,22(11),1386-1396","journal-title":"Mult Scler"},{"key":"ref=118","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1016\/j.jneuroim.2013.02.013","volume":"258","author":"Duchi S.","year":"2013","unstructured":"Duchi S.; Ovadia H.; Touitou E.; Nasal administration of drugs as a new non-invasive strategy for efficient treatment of multiple sclerosis. J Neuroimmunol 2013,258(1-2),32-40","journal-title":"J Neuroimmunol"},{"key":"ref=119","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1016\/j.jneuroim.2015.08.017","volume":"288","author":"Zhang K.","year":"2015","unstructured":"Zhang K.; Ge Z.; Xue Z.; Chrysin suppresses human CD14(+) monocyte-derived dendritic cells and ameliorates experimental autoimmune encephalomyelitis. J Neuroimmunol 2015,288,13-20","journal-title":"J Neuroimmunol"},{"key":"ref=120","doi-asserted-by":"publisher","DOI":"10.1016\/j.jneuroim.2019.577007","volume":"335","author":"Del Fabbro L.","year":"2019","unstructured":"Del Fabbro L.; de Gomes M.G.; Souza L.C.; Chrysin suppress immune responses and protects from experimental autoimmune encephalomyelitis in mice. J Neuroimmunol 2019,335","journal-title":"J Neuroimmunol"},{"key":"ref=121","doi-asserted-by":"publisher","first-page":"280","DOI":"10.1016\/j.ijpharm.2016.09.042","volume":"513","author":"Lungare S.","year":"2016","unstructured":"Lungare S.; Hallam K.; Badhan R.K.S.; Phytochemical-loaded mesoporous silica nanoparticles for nose-to-brain olfactory drug delivery. Int J Pharm 2016,513(1-2),280-293","journal-title":"Int J Pharm"},{"key":"ref=122","doi-asserted-by":"publisher","first-page":"657","DOI":"10.3389\/fnins.2018.00657","volume":"12","author":"Tao L.","year":"2018","unstructured":"Tao L.; Zhang L.; Gao R.; Jiang F.; Cao J.; Liu H.; Andrographolide alleviates acute brain injury in a rat model of traumatic brain injury: possible involvement of inflammatory signaling. Front Neurosci 2018,12,657","journal-title":"Front Neurosci"},{"key":"ref=123","doi-asserted-by":"publisher","first-page":"285","DOI":"10.1016\/j.lfs.2019.05.007","volume":"228","author":"Rashno M.","year":"2019","unstructured":"Rashno M.; Sarkaki A.; Farbood Y.; Therapeutic effects of chrysin in a rat model of traumatic brain injury: a behavioral, biochemical, and histological study. Life Sci 2019,228,285-294","journal-title":"Life Sci"},{"key":"ref=124","doi-asserted-by":"publisher","first-page":"337","DOI":"10.1007\/s11064-016-2077-8","volume":"42","author":"Ding H.","year":"2017","unstructured":"Ding H.; Wang H.; Zhu L.; Wei W.; Ursolic acid ameliorates early brain injury after experimental traumatic brain injury in mice by activating the Nrf2 pathway. Neurochem Res 2017,42(2),337-346","journal-title":"Neurochem Res"},{"key":"ref=125","doi-asserted-by":"publisher","first-page":"585","DOI":"10.1093\/ijnp\/pyz032","volume":"22","author":"Zhang J-J.","year":"2019","unstructured":"Zhang J-J.; Gao T-T.; Wang Y.; Andrographolide exerts significant antidepressant-like effects involving the hippocampal BDNF system in mice. Int J Neuropsychopharmacol 2019,22(9),585-600","journal-title":"Int J Neuropsychopharmacol"},{"key":"ref=126","doi-asserted-by":"publisher","DOI":"10.1016\/j.taap.2019.114688","volume":"379","author":"Geng J.","year":"2019","unstructured":"Geng J.; Liu J.; Yuan X.; Liu W.; Guo W.; Andrographolide triggers autophagy-mediated inflammation inhibition and attenuates chronic unpredictable mild stress (CUMS)-induced depressive-like behavior in mice. Toxicol Appl Pharmacol 2019,379","journal-title":"Toxicol Appl Pharmacol"},{"key":"ref=127","doi-asserted-by":"publisher","first-page":"154","DOI":"10.1016\/j.cbi.2016.11.005","volume":"260","author":"Filho C.B.","year":"2016","unstructured":"Filho C.B.; Jesse C.R.; Donato F.; Chrysin promotes attenuation of depressive-like behavior and hippocampal dysfunction resulting from olfactory bulbectomy in mice. Chem Biol Interact 2016,260,154-162","journal-title":"Chem Biol Interact"},{"key":"ref=128","doi-asserted-by":"publisher","first-page":"214","DOI":"10.1016\/j.ijpharm.2018.03.055","volume":"543","author":"Colombo M.","year":"2018","unstructured":"Colombo M.; Figueir\u00f3 F.; de Fraga Dias A.; Teixeira H.F.; Battastini A.M.O.; Koester L.S.; Kaempferol-loaded mucoadhesive nanoemulsion for intranasal administration reduces glioma growth in vitro. Int J Pharm 2018,543(1-2),214-223","journal-title":"Int J Pharm"},{"key":"ref=129","doi-asserted-by":"publisher","first-page":"1029","DOI":"10.1007\/s40263-017-0474-4","volume":"31","author":"Ramos-Hryb A.B.","year":"2017","unstructured":"Ramos-Hryb A.B.; Pazini F.L.; Kaster M.P.; Rodrigues A.L.S.; Therapeutic potential of ursolic acid to manage neurodegenerative and psychiatric diseases. CNS Drugs 2017,31(12),1029-1041","journal-title":"CNS Drugs"},{"key":"ref=130","doi-asserted-by":"publisher","first-page":"571","DOI":"10.1007\/s10571-016-0400-1","volume":"37","author":"Pearn M.L.","year":"2017","unstructured":"Pearn M.L.; Niesman I.R.; Egawa J.; Pathophysiology associated with traumatic brain injury: current treatments and potential novel therapeutics. Cell Mol Neurobiol 2017,37(4),571-585","journal-title":"Cell Mol Neurobiol"},{"key":"ref=131","doi-asserted-by":"publisher","first-page":"10240","DOI":"10.1523\/JNEUROSCI.1683-07.2007","volume":"27","author":"Zhao J.","year":"2007","unstructured":"Zhao J.; Moore A.N.; Redell J.B.; Dash P.K.; Enhancing expression of Nrf2-driven genes protects the blood brain barrier after brain injury. J Neurosci 2007,27(38),10240-10248","journal-title":"J Neurosci"},{"key":"ref=132","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1016\/j.bbr.2017.12.025","volume":"341","author":"Jesulola E.","year":"2018","unstructured":"Jesulola E.; Micalos P.; Baguley I.J.; Understanding the pathophysiology of depression: from monoamines to the neurogenesis hypothesis model - are we there yet? Behav Brain Res 2018,341,79-90","journal-title":"Behav Brain Res"},{"key":"ref=133","doi-asserted-by":"publisher","first-page":"444","DOI":"10.1016\/j.pbb.2008.01.020","volume":"89","author":"Liang X.","year":"2008","unstructured":"Liang X.; Xu N.; Cui S.; Antidepressant-like effect of asiaticoside in mice. Pharmacol Biochem Behav 2008,89(3),444-449","journal-title":"Pharmacol Biochem Behav"},{"key":"ref=134","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1016\/j.brainresbull.2015.03.006","volume":"114","author":"Luo L.","year":"2015","unstructured":"Luo L.; Liu X.L.; Mu R.H.; Hippocampal BDNF signaling restored with chronic asiaticoside treatment in depression-like mice. Brain Res Bull 2015,114,62-69","journal-title":"Brain Res Bull"},{"key":"ref=135","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1016\/j.neulet.2017.02.068","volume":"646","author":"Hou T.","year":"2017","unstructured":"Hou T.; Li X.; Peng C.; Borneol enhances the antidepressant effects of asiaticoside by promoting its distribution into the brain. Neurosci Lett 2017,646,56-61","journal-title":"Neurosci Lett"},{"key":"ref=136","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.bbr.2014.03.052","volume":"268","author":"Hurley L.L.","year":"2014","unstructured":"Hurley L.L.; Akinfiresoye L.; Kalejaiye O.; Tizabi Y.; Antidepressant effects of resveratrol in an animal model of depression. Behav Brain Res 2014,268,1-7","journal-title":"Behav Brain Res"},{"key":"ref=137","doi-asserted-by":"publisher","first-page":"4543","DOI":"10.1007\/s12035-017-0680-6","volume":"55","author":"de Oliveira M.R.","year":"2018","unstructured":"de Oliveira M.R.; Chenet A.L.; Duarte A.R.; Scaini G.; Quevedo J.; Molecular mechanisms underlying the anti-depressant effects of resveratrol: a review. Mol Neurobiol 2018,55(6),4543-4559","journal-title":"Mol Neurobiol"},{"key":"ref=138","doi-asserted-by":"publisher","first-page":"1240","DOI":"10.1016\/j.pharep.2017.05.009","volume":"69","author":"Ramos-Hryb A.B.","year":"2017","unstructured":"Ramos-Hryb A.B.; Cunha M.P.; Pazini F.L.; Ursolic acid affords antidepressant-like effects in mice through the activation of PKA, PKC, CAMK-II and MEK1\/2. Pharmacol Rep 2017,69(6),1240-1246","journal-title":"Pharmacol Rep"},{"key":"ref=139","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1016\/j.physbeh.2017.09.024","volume":"182","author":"Chen W.J.","year":"2017","unstructured":"Chen W.J.; Du J.K.; Hu X.; Protective effects of resveratrol on mitochondrial function in the hippocampus improves inflammation-induced depressive-like behavior. Physiol Behav 2017,182,54-61","journal-title":"Physiol Behav"},{"key":"ref=140","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1016\/S0021-9673(98)00697-9","volume":"825","author":"Brolis M.","year":"1998","unstructured":"Brolis M.; Gabetta B.; Fuzzati N.; Pace R.; Panzeri F.; Peterlongo F.; Identification by high-performance liquid chromatography-diode array detection-mass spectrometry and quantification by high-performance liquid chromatography - UV absorbance detection of active constituents of hypericum perforatum. J Chromatogr A 1998,825,9-16","journal-title":"J Chromatogr A"},{"key":"ref=141","doi-asserted-by":"publisher","first-page":"577","DOI":"10.1055\/s-2002-32908","volume":"68","author":"N\u00f6ldner M.","year":"2002","unstructured":"N\u00f6ldner M.; Sch\u00f6tz K.; Rutin is essential for the antidepressant activity of Hypericum perforatum extracts in the forced swimming test. Planta Med 2002,68(7),577-580","journal-title":"Planta Med"},{"key":"ref=142","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1016\/j.pbb.2015.07.003","volume":"136","author":"Holzmann I.","year":"2015","unstructured":"Holzmann I.; da Silva L.M.; Corr\u00eaa da Silva J.A.; Steimbach V.M.B.; de Souza M.M.; Antidepressant-like effect of quercetin in bulbectomized mice and involvement of the antioxidant defenses, and the glutamatergic and oxidonitrergic pathways. Pharmacol Biochem Behav 2015,136,55-63","journal-title":"Pharmacol Biochem Behav"},{"key":"ref=143","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1016\/j.neuroscience.2013.09.044","volume":"255","author":"Rinwa P.","year":"2013","unstructured":"Rinwa P.; Kumar A.; Quercetin suppress microglial neuroinflammatory response and induce antidepressent-like effect in olfactory bulbectomized rats. Neuroscience 2013,255,86-98","journal-title":"Neuroscience"},{"key":"ref=144","first-page":"149","volume":"1","year":"2002","unstructured":"monographs on selected medicinal plants - volume 2: herba hyperici. WHO Monogr Sel Med Plants WHO2002,1,149-171","journal-title":"WHO Monogr Sel Med Plants"},{"key":"ref=145","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1016\/j.ejphar.2008.03.021","volume":"587","author":"Machado D.G.","year":"2008","unstructured":"Machado D.G.; Bettio L.E.B.; Cunha M.P.; Antidepressant-like effect of rutin isolated from the ethanolic extract from Schinus molle L. in mice: evidence for the involvement of the serotonergic and noradrenergic systems. Eur J Pharmacol 2008,587(1-3),163-168","journal-title":"Eur J Pharmacol"},{"key":"ref=146","doi-asserted-by":"publisher","first-page":"717","DOI":"10.1080\/21691401.2017.1337024","volume":"46","author":"Ahmad N.","year":"2018","unstructured":"Ahmad N.; Ahmad R.; Naqvi A.A.; Intranasal delivery of quercetin-loaded mucoadhesive nanoemulsion for treatment of cerebral ischaemia. Artif Cells Nanomed Biotechnol 2018,46(4),717-729","journal-title":"Artif Cells Nanomed Biotechnol"},{"key":"ref=147","doi-asserted-by":"publisher","first-page":"2873","DOI":"10.1007\/s00018-009-0053-z","volume":"66","author":"Hillaireau H.","year":"2009","unstructured":"Hillaireau H.; Couvreur P.; Nanocarriers\u2019 entry into the cell: relevance to drug delivery. Cell Mol Life Sci 2009,66(17),2873-2896","journal-title":"Cell Mol Life Sci"},{"key":"ref=148","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3390\/pharmaceutics10030116","volume":"10","author":"G\u00e4nger S.","year":"2018","unstructured":"G\u00e4nger S.; Schindowski K.; Tailoring formulations for intranasal nose-to-brain delivery: a review on architecture, physico-chemical characteristics and mucociliary clearance of the nasal olfactory mucosa. Pharmaceutics 2018,10(3),1-28","journal-title":"Pharmaceutics"},{"key":"ref=149","doi-asserted-by":"publisher","first-page":"1020","DOI":"10.3390\/cancers5031020","volume":"5","author":"van Woensel M.","year":"2013","unstructured":"van Woensel M.; Wauthoz N.; Rosi\u00e8re R.; Formulations for intranasal delivery of pharmacological agents to combat brain disease: a new opportunity to tackle GBM? Cancers (Basel) 2013,5(3),1020-1048","journal-title":"Cancers (Basel)"},{"key":"ref=150","doi-asserted-by":"publisher","first-page":"735","DOI":"10.1080\/02652048.2016.1260659","volume":"33","author":"Martignoni I.","year":"2016","unstructured":"Martignoni I.; Trotta V.; Lee W.H.; Resveratrol solid lipid microparticles as dry powder formulation for nasal delivery, characterization and in vitro deposition study. J Microencapsul 2016,33(8),735-742","journal-title":"J Microencapsul"},{"key":"ref=151","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1631\/jzus.B1000121","volume":"12","author":"Lu Y.","year":"2011","unstructured":"Lu Y.; Du S.Y.; Chen X.L.; Enhancing effect of natural borneol on the absorption of geniposide in rat via intranasal administration. J Zhejiang Univ Sci B 2011,12(2),143-148","journal-title":"J Zhejiang Univ Sci B"},{"key":"ref=152","doi-asserted-by":"publisher","first-page":"14127","DOI":"10.3390\/ijms131114127","volume":"13","author":"Lu Y.","year":"2012","unstructured":"Lu Y.; Du S.; Bai J.; Li P.; Wen R.; Zhao X.; Bioavailability and brain-targeting of geniposide in gardenia-borneol co-compound by different administration routes in mice. Int J Mol Sci 2012,13(11),14127-14135","journal-title":"Int J Mol Sci"},{"key":"ref=153","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0101414","volume":"9","author":"Chen Z.","year":"2014","unstructured":"Chen Z.; Gong X.; Lu Y.; Enhancing effect of borneol and muscone on geniposide transport across the human nasal epithelial cell monolayer. PLoS One 2014,9(7)","journal-title":"PLoS One"},{"key":"ref=154","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0189478","volume":"12","author":"Wang Y.","year":"2017","unstructured":"Wang Y.; Jiang S.; Wang H.; Bie H.; A mucoadhesive, thermoreversible in situ nasal gel of geniposide for neurodegenerative diseases. PLoS One 2017,12(12)","journal-title":"PLoS One"},{"key":"ref=155","doi-asserted-by":"publisher","first-page":"2105","DOI":"10.2217\/nnm-2018-0417","volume":"14","author":"Wang L.","year":"2019","unstructured":"Wang L.; Zhao X.; Du J.; Liu M.; Feng J.; Hu K.; Improved brain delivery of pueraria flavones via intranasal administration of borneol-modified solid lipid nanoparticles. Nanomedicine (Lond) 2019,14(16),2105-2119","journal-title":"Nanomedicine (Lond)"},{"key":"ref=156","doi-asserted-by":"publisher","first-page":"394","DOI":"10.1039\/C4FO00817K","volume":"6","author":"Ferri P.","year":"2015","unstructured":"Ferri P.; Angelino D.; Gennari L.; Enhancement of flavonoid ability to cross the blood-brain barrier of rats by co-administration with \u03b1-tocopherol. Food Funct 2015,6(2),394-400","journal-title":"Food Funct"},{"key":"ref=157","doi-asserted-by":"publisher","first-page":"2581","DOI":"10.2147\/DDDT.S143029","volume":"11","author":"Zhang L.","year":"2017","unstructured":"Zhang L.; Du S.Y.; Lu Y.; Puerarin transport across rat nasal epithelial cells and the influence of compatibility with peoniflorin and menthol. Drug Des Devel Ther 2017,11,2581-2593","journal-title":"Drug Des Devel Ther"},{"key":"ref=158","doi-asserted-by":"publisher","first-page":"1037","DOI":"10.1080\/10717544.2017.1346002","volume":"24","author":"Zhang Q.L.","year":"2017","unstructured":"Zhang Q.L.; Fu B.M.; Zhang Z.J.; Borneol, a novel agent that improves central nervous system drug delivery by enhancing blood-brain barrier permeability. Drug Deliv 2017,24(1),1037-1044","journal-title":"Drug Deliv"},{"key":"ref=159","doi-asserted-by":"publisher","first-page":"843","DOI":"10.1016\/j.apsb.2019.01.006","volume":"9","author":"Gao C.","year":"2019","unstructured":"Gao C.; Liang J.; Zhu Y.; Menthol-modified casein nanoparticles loading 10-hydroxycamptothecin for glioma targeting therapy. Acta Pharm Sin B 2019,9(4),843-857","journal-title":"Acta Pharm Sin B"},{"key":"ref=160","doi-asserted-by":"publisher","first-page":"23","DOI":"10.3390\/molecules23102478","volume":"23","author":"Bruni N.","year":"2018","unstructured":"Bruni N.; Della Pepa C.; Oliaro-Bosso S.; Pessione E.; Gastaldi D.; Dosio F.; Cannabinoid delivery systems for pain and inflammation treatment. Molecules 2018,23(10),23","journal-title":"Molecules"},{"key":"ref=161","doi-asserted-by":"publisher","DOI":"10.1155\/2016\/2571060","author":"Xiao XY","year":"Biomed Res Int 2016; (2016): 2571060","unstructured":"Xiao XY; Zhu YX; Bu JY; Li GW; Zhou JH; Zhou SP; Evaluation of neuroprotective effect of thymoquinone nanoformulation in the rodent cerebral ischemia-reperfusion model Biomed Res Int 2016; (2016): 2571060","journal-title":"Evaluation of neuroprotective effect of thymoquinone nanoformulation in the rodent cerebral ischemia-reperfusion model"},{"key":"ref=162","doi-asserted-by":"publisher","first-page":"1377","DOI":"10.3390\/polym3031377","volume":"3","author":"Makadia H.K.","year":"2011","unstructured":"Makadia H.K.; Siegel S.J.; Poly Lactic-co-Glycolic Acid (PLGA) as biodegradable controlled drug delivery carrier. Polymers (Basel) 2011,3(3),1377-1397","journal-title":"Polymers (Basel)"},{"key":"ref=163","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1007\/s13346-017-0438-8","volume":"8","author":"Pan L.","year":"2018","unstructured":"Pan L.; Zhou J.; Ju F.; Zhu H.; Intranasal delivery of \u03b1-asarone to the brain with lactoferrin-modified mPEG-PLA nanoparticles prepared by premix membrane emulsification. Drug Deliv Transl Res 2018,8(1),83-96","journal-title":"Drug Deliv Transl Res"},{"key":"ref=164","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3390\/pharmaceutics10010034","volume":"10","author":"Sonvico F.","year":"2018","unstructured":"Sonvico F.; Clementino A.; Buttini F.; Surface-modified nanocarriers for nose-to-brain delivery: from bioadhesion to targeting. Pharmaceutics 2018,10(1),1-34","journal-title":"Pharmaceutics"},{"key":"ref=165","doi-asserted-by":"publisher","first-page":"686","DOI":"10.1166\/jbn.2019.2724","volume":"15","author":"Li Y.","year":"2019","unstructured":"Li Y.; Wang C.; Zong S.; The trigeminal pathway dominates the nose-to-brain transportation of intact polymeric nanoparticles: evidence from aggregation-caused quenching probes. J Biomed Nanotechnol 2019,15(4),686-702","journal-title":"J Biomed Nanotechnol"},{"key":"ref=166","doi-asserted-by":"publisher","first-page":"584","DOI":"10.1055\/a-0596-7288","volume":"68","author":"Ahmad N.","year":"2018","unstructured":"Ahmad N.; Ahmad R.; Alam M.A.; Ahmad F.J.; Quantification and brain targeting of eugenol-loaded surface modified nanoparticles through intranasal route in the treatment of cerebral ischemia. Drug Res (Stuttg) 2018,68(10),584-595","journal-title":"Drug Res (Stuttg)"},{"key":"ref=167","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1016\/S0378-5173(02)00483-0","volume":"249","author":"Chawla J.S.","year":"2002","unstructured":"Chawla J.S.; Amiji M.M.; Biodegradable poly(\u03b5 -caprolactone) nanoparticles for tumor-targeted delivery of tamoxifen. Int J Pharm 2002,249(1-2),127-138","journal-title":"Int J Pharm"},{"key":"ref=168","doi-asserted-by":"publisher","first-page":"697","DOI":"10.1007\/978-1-4939-3389-1_45","volume":"1404","author":"Jesus S.","year":"2016","unstructured":"Jesus S.; Soares E.; Borges O.; Poly-\u03b5-caprolactone\/chitosan and chitosan particles: two recombinant antigen delivery systems for intranasal vaccination. Methods Mol Biol 2016,1404,697-713","journal-title":"Methods Mol Biol"},{"key":"ref=169","doi-asserted-by":"publisher","first-page":"272","DOI":"10.1016\/j.etap.2012.04.012","volume":"34","author":"Li W.","year":"2012","unstructured":"Li W.; Zhou Y.; Zhao N.; Hao B.; Wang X.; Kong P.; Pharmacokinetic behavior and efficiency of acetylcholinesterase inhibition in rat brain after intranasal administration of galanthamine hydrobromide loaded flexible liposomes. Environ Toxicol Pharmacol 2012,34(2),272-279","journal-title":"Environ Toxicol Pharmacol"},{"key":"ref=170","doi-asserted-by":"publisher","first-page":"933","DOI":"10.1002\/jps.22333","volume":"100","author":"Yu A.","year":"2011","unstructured":"Yu A.; Wang H.; Wang J.; Formulation optimization and bioavailability after oral and nasal administration in rabbits of puerarin-loaded microemulsion. J Pharm Sci 2011,100(3),933-941","journal-title":"J Pharm Sci"},{"key":"ref=171","doi-asserted-by":"publisher","DOI":"10.1088\/0957-4484\/25\/48\/485102","volume":"25","author":"Pangeni R.","year":"2014","unstructured":"Pangeni R.; Sharma S.; Mustafa G.; Ali J.; Baboota S.; Vitamin E loaded resveratrol nanoemulsion for brain targeting for the treatment of Parkinson\u2019s disease by reducing oxidative stress. Nanotechnology 2014,25(48)","journal-title":"Nanotechnology"},{"key":"ref=172","doi-asserted-by":"publisher","first-page":"320","DOI":"10.1016\/j.ijbiomac.2016.03.019","volume":"88","author":"Ahmad N.","year":"2016","unstructured":"Ahmad N.; Ahmad R.; Alam M.A.; Samim M.; Iqbal Z.; Ahmad F.J.; Quantification and evaluation of thymoquinone loaded mucoadhesive nanoemulsion for treatment of cerebral ischemia. Int J Biol Macromol 2016,88,320-332","journal-title":"Int J Biol Macromol"},{"key":"ref=173","doi-asserted-by":"publisher","first-page":"961","DOI":"10.3233\/JAD-160355","volume":"59","author":"Vaz G.R.","year":"2017","unstructured":"Vaz G.R.; H\u00e4drich G.; Bidone J.; Development of nasal lipid nanocarriers containing curcumin for brain targeting. J Alzheimers Dis 2017,59(3),961-974","journal-title":"J Alzheimers Dis"},{"key":"ref=174","doi-asserted-by":"crossref","first-page":"1326","DOI":"10.3109\/10717544.2014.975382","volume":"23","author":"Madane R.G.","year":"2016","unstructured":"Madane R.G.; Mahajan H.S.; Curcumin-loaded nanostructured lipid carriers (NLCs) for nasal administration: design, characterization, and in vivo study. Drug Deliv 2016,23(4),1326-1334","journal-title":"Drug Deliv"},{"key":"ref=175","doi-asserted-by":"publisher","first-page":"523","DOI":"10.1615\/CritRevTherDrugCarrierSyst.v26.i6.10","volume":"26","author":"Puri A.","year":"2009","unstructured":"Puri A.; Loomis K.; Smith B.; Lipid-based nanoparticles as pharmaceutical drug carriers: from concepts to clinic. Crit Rev Ther Drug Carrier Syst 2009,26(6),523-580","journal-title":"Crit Rev Ther Drug Carrier Syst"},{"key":"ref=176","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1016\/j.jconrel.2007.12.018","volume":"127","author":"Kaur I.P.","year":"2008","unstructured":"Kaur I.P.; Bhandari R.; Bhandari S.; Kakkar V.; Potential of solid lipid nanoparticles in brain targeting. J Control Release 2008,127(2),97-109","journal-title":"J Control Release"},{"key":"ref=177","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1016\/j.drudis.2015.10.016","volume":"21","author":"Karavasili C.","year":"2016","unstructured":"Karavasili C.; Fatouros D.G.; Smart materials: in situ gel-forming systems for nasal delivery. Drug Discov Today 2016,21(1),157-166","journal-title":"Drug Discov Today"},{"key":"ref=178","doi-asserted-by":"publisher","first-page":"1578","DOI":"10.1016\/j.biopha.2018.07.127","volume":"106","author":"Khan K.","year":"2018","unstructured":"Khan K.; Aqil M.; Imam S.S.; Ursolic acid loaded intra nasal nano lipid vesicles for brain tumour: formulation, optimization, in-vivo brain\/plasma distribution study and histopathological assessment. Biomed Pharmacother 2018,106,1578-1585","journal-title":"Biomed Pharmacother"},{"key":"ref=179","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1208\/s12249-019-1353-8","volume":"20","author":"Salem H.F.","year":"2019","unstructured":"Salem H.F.; Kharshoum R.M.; Abou-Taleb H.A.; Naguib D.M.; Nanosized transferosome-based intranasal in situ gel for brain targeting of resveratrol: formulation, optimization, in vitro evaluation, and in vivo pharmacokinetic study. AAPS PharmSciTech 2019,20(5),181","journal-title":"AAPS PharmSciTech"},{"key":"ref=180","doi-asserted-by":"publisher","first-page":"376","DOI":"10.1016\/j.colsurfb.2016.08.011","volume":"147","author":"Hao J.","year":"2016","unstructured":"Hao J.; Zhao J.; Zhang S.; Fabrication of an ionic-sensitive in situ gel loaded with resveratrol nanosuspensions intended for direct nose-to-brain delivery. Colloids Surf B Biointerfaces 2016,147,376-386","journal-title":"Colloids Surf B Biointerfaces"},{"key":"ref=181","doi-asserted-by":"publisher","first-page":"2958","DOI":"10.1002\/anie.201804067","volume":"58","author":"Barriga H.M.G.","year":"2019","unstructured":"Barriga H.M.G.; Holme M.N.; Stevens M.M.; Cubosomes: the next generation of smart lipid nanoparticles? Angew Chem Int Ed Engl 2019,58(10),2958-2978","journal-title":"Angew Chem Int Ed Engl"},{"key":"ref=182","doi-asserted-by":"publisher","first-page":"1606","DOI":"10.1038\/mt.2010.105","volume":"18","author":"Sun D.","year":"2010","unstructured":"Sun D.; Zhuang X.; Xiang X.; A novel nanoparticle drug delivery system: the anti-inflammatory activity of curcumin is enhanced when encapsulated in exosomes. Mol Ther 2010,18(9),1606-1614","journal-title":"Mol Ther"},{"key":"ref=183","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1016\/j.biomaterials.2017.10.012","volume":"150","author":"Tian T.","year":"2018","unstructured":"Tian T.; Zhang H.X.; He C.P.; Surface functionalized exosomes as targeted drug delivery vehicles for cerebral ischemia therapy. Biomaterials 2018,150,137-149","journal-title":"Biomaterials"},{"key":"ref=184","doi-asserted-by":"publisher","first-page":"1769","DOI":"10.1038\/mt.2011.164","volume":"19","author":"Zhuang X.","year":"2011","unstructured":"Zhuang X.; Xiang X.; Grizzle W.; Treatment of brain inflammatory diseases by delivering exosome encapsulated anti-inflammatory drugs from the nasal region to the brain. Mol Ther 2011,19(10),1769-1779","journal-title":"Mol Ther"},{"key":"ref=185","doi-asserted-by":"publisher","first-page":"360","DOI":"10.1016\/j.biocel.2016.09.002","volume":"79","author":"Kalani A.","year":"2016","unstructured":"Kalani A.; Chaturvedi P.; Kamat P.K.; Curcumin-loaded embryonic stem cell exosomes restored neurovascular unit following ischemia-reperfusion injury. Int J Biochem Cell Biol 2016,79,360-369","journal-title":"Int J Biochem Cell Biol"},{"key":"ref=186","doi-asserted-by":"publisher","first-page":"1754","DOI":"10.1038\/mt.2011.198","volume":"19","author":"Lakhal S.","year":"2011","unstructured":"Lakhal S.; Wood M.J.A.; Intranasal exosomes for treatment of neuroinflammation? Prospects and limitations. Mol Ther 2011,19(10),1754-1756","journal-title":"Mol Ther"},{"key":"ref=187","doi-asserted-by":"publisher","first-page":"2227","DOI":"10.2147\/DDDT.S110247","volume":"10","author":"Zhang L.","year":"2016","unstructured":"Zhang L.; Du S.Y.; Lu Y.; Puerarin transport across a Calu-3 cell monolayer - an in vitro model of nasal mucosa permeability and the influence of paeoniflorin and menthol. Drug Des Devel Ther 2016,10,2227-2237","journal-title":"Drug Des Devel Ther"},{"key":"ref=188","doi-asserted-by":"publisher","first-page":"1077","DOI":"10.1080\/10717544.2017.1357148","volume":"24","author":"Fatouh A.M.","year":"2017","unstructured":"Fatouh A.M.; Elshafeey A.H.; Abdelbary A.; Agomelatine-based in situ gels for brain targeting via the nasal route: statistical optimization, in vitro, and in vivo evaluation. Drug Deliv 2017,24(1),1077-1085","journal-title":"Drug Deliv"},{"key":"ref=189","doi-asserted-by":"publisher","first-page":"719","DOI":"10.1007\/s13318-016-0388-4","volume":"42","author":"Li P.","year":"2017","unstructured":"Li P.; Bai J.; Dong B.; In vivo pharmacokinetics of puerarin via different drug administration routes based on middle cerebral artery occlusion model. Eur J Drug Metab Pharmacokinet 2017,42(4),719-727","journal-title":"Eur J Drug Metab Pharmacokinet"},{"key":"ref=190","doi-asserted-by":"publisher","first-page":"1294","DOI":"10.1208\/s12248-017-0108-2","volume":"19","author":"Hammarlund-Udenaes M.","year":"2017","unstructured":"Hammarlund-Udenaes M.; Microdialysis as an important technique in systems pharmacology - a historical and methodological review. AAPS J 2017,19(5),1294-1303","journal-title":"AAPS J"},{"key":"ref=191","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1016\/j.jconrel.2018.05.011","volume":"281","author":"Agrawal M.","year":"2018","unstructured":"Agrawal M.; Saraf S.; Saraf S.; Nose-to-brain drug delivery: an update on clinical challenges and progress towards approval of anti-Alzheimer drugs. J Control Release 2018,281,139-177","journal-title":"J Control Release"},{"key":"ref=192","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1016\/j.phymed.2018.09.230","volume":"51","author":"Lee H.J.","year":"2018","unstructured":"Lee H.J.; Ahn S.M.; Pak M.E.; Positive effects of \u03b1-asarone on transplanted neural progenitor cells in a murine model of ischemic stroke. Phytomedicine 2018,51,151-161","journal-title":"Phytomedicine"},{"key":"ref=193","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1016\/j.neuropharm.2015.04.037","volume":"97","author":"Kim B.W.","year":"2015","unstructured":"Kim B.W.; Koppula S.; Kumar H.; \u03b1-Asarone attenuates microglia-mediated neuroinflammation by inhibiting NF kappa B activation and mitigates MPTP-induced behavioral deficits in a mouse model of Parkinson\u2019s disease. Neuropharmacology 2015,97,46-57","journal-title":"Neuropharmacology"},{"key":"ref=194","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1016\/j.phymed.2017.04.003","volume":"32","author":"Chellian R.","year":"2017","unstructured":"Chellian R.; Pandy V.; Mohamed Z.; Pharmacology and toxicology of \u03b1- and \u03b2-Asarone: a review of preclinical evidence. Phytomedicine 2017,32,41-58","journal-title":"Phytomedicine"},{"key":"ref=195","doi-asserted-by":"publisher","first-page":"302","DOI":"10.1016\/j.colsurfb.2017.10.062","volume":"161","author":"Graverini G.","year":"2018","unstructured":"Graverini G.; Piazzini V.; Landucci E.; Solid lipid nanoparticles for delivery of andrographolide across the blood-brain barrier: in vitro and in vivo evaluation. Colloids Surf B Biointerfaces 2018,161,302-313","journal-title":"Colloids Surf B Biointerfaces"},{"key":"ref=196","doi-asserted-by":"publisher","first-page":"910","DOI":"10.3389\/fphar.2019.00910","volume":"10","author":"Bilia A.R.","year":"2019","unstructured":"Bilia A.R.; Nardiello P.; Piazzini V.; Successful brain delivery of andrographolide loaded in human albumin nanoparticles to TgCRND8 mice, an Alzheimer\u2019s disease mouse model. Front Pharmacol 2019,10,910","journal-title":"Front Pharmacol"},{"key":"ref=197","doi-asserted-by":"publisher","DOI":"10.1016\/j.biopha.2019.109078","volume":"117","author":"Lu J.","year":"2019","unstructured":"Lu J.; Ma Y.; Wu J.; A review for the neuroprotective effects of andrographolide in the central nervous system. Biomed Pharmacother 2019,117","journal-title":"Biomed Pharmacother"},{"key":"ref=198","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3390\/s19102275","volume":"19","author":"Chiu S-P.","year":"2019","unstructured":"Chiu S-P.; Batsaikhan B.; Huang H-M.; Wang J-Y.; Application of electric cell-substrate impedance sensing to investigate the cytotoxic effects of andrographolide on U-87 MG glioblastoma cell migration and apoptosis. Sensors (Basel) 2019,19(10),1-15","journal-title":"Sensors (Basel)"},{"key":"ref=199","doi-asserted-by":"publisher","first-page":"1088","DOI":"10.3109\/03639041003657295","volume":"36","author":"Paudel K.S.","year":"2010","unstructured":"Paudel K.S.; Hammell D.C.; Agu R.U.; Valiveti S.; Stinchcomb A.L.; Cannabidiol bioavailability after nasal and transdermal application: effect of permeation enhancers. Drug Dev Ind Pharm 2010,36(9),1088-1097","journal-title":"Drug Dev Ind Pharm"},{"key":"ref=200","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1016\/j.cbi.2017.10.019","volume":"279","author":"Goes A.T.R.","year":"2018","unstructured":"Goes A.T.R.; Jesse C.R.; Antunes M.S.; Protective role of chrysin on 6-hydroxydopamine-induced neurodegeneration a mouse model of Parkinson\u2019s disease: involvement of neuroinflammation and neurotrophins. Chem Biol Interact 2018,279,111-120","journal-title":"Chem Biol Interact"},{"key":"ref=201","doi-asserted-by":"publisher","DOI":"10.1016\/j.neulet.2019.134382","volume":"709","author":"Krishnamoorthy A.","year":"2019","unstructured":"Krishnamoorthy A.; Sevanan M.; Mani S.; Balu M.; Balaji S.; P R. Chrysin restores MPTP induced neuroinflammation, oxidative stress and neurotrophic factors in an acute Parkinson\u2019s disease mouse model. Neurosci Lett 2019,709","journal-title":"Neurosci Lett"},{"key":"ref=202","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1007\/s12031-017-1006-x","volume":"64","author":"Huang L.","year":"2018","unstructured":"Huang L.; Chen C.; Zhang X.; Neuroprotective effect of curcumin against cerebral ischemia-reperfusion via mediating autophagy and inflammation. J Mol Neurosci 2018,64(1),129-139","journal-title":"J Mol Neurosci"},{"key":"ref=203","doi-asserted-by":"publisher","first-page":"2055","DOI":"10.3109\/03639045.2015.1062897","volume":"41","author":"Hanafy A.S.","year":"2015","unstructured":"Hanafy A.S.; Farid R.M.; ElGamal S.S.; Complexation as an approach to entrap cationic drugs into cationic nanoparticles administered intranasally for Alzheimer\u2019s disease management: preparation and detection in rat brain. Drug Dev Ind Pharm 2015,41(12),2055-2068","journal-title":"Drug Dev Ind Pharm"},{"key":"ref=204","first-page":"157","volume":"68","author":"Heinrich M.","year":"2010","unstructured":"Heinrich M.; Galanthamine from galanthus and other amaryllidaceae - chemistry and biology based on traditional use. In: Alkaloids Chem Biol 2010,68,157-165","journal-title":"In: Alkaloids Chem Biol"},{"key":"ref=205","doi-asserted-by":"publisher","first-page":"11","DOI":"10.3390\/pharmaceutics11010008","volume":"11","author":"Rassu G.","year":"2018","unstructured":"Rassu G.; Porcu E.P.; Fancello S.; Intranasal delivery of genistein-loaded nanoparticles as a potential preventive system against neurodegenerative disorders. Pharmaceutics 2018,11(1),11","journal-title":"Pharmaceutics"},{"key":"ref=206","doi-asserted-by":"publisher","first-page":"353","DOI":"10.3389\/fnagi.2017.00353","volume":"9","author":"Kuang X.","year":"2017","unstructured":"Kuang X.; Zhou H.J.; Thorne A.H.; Chen X.N.; Li L.J.; Du J.R.; Neuroprotective effect of ligustilide through induction of \u03b1-secretase processing of both APP and Klotho in a mouse model of Alzheimer\u2019s disease. Front Aging Neurosci 2017,9,353","journal-title":"Front Aging Neurosci"},{"key":"ref=207","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1016\/j.freeradbiomed.2014.03.028","volume":"71","author":"Kuang X.","year":"2014","unstructured":"Kuang X.; Wang L.F.; Yu L.; Ligustilide ameliorates neuroinflammation and brain injury in focal cerebral ischemia\/reperfusion rats: involvement of inhibition of TLR4\/peroxiredoxin 6 signaling. Free Radic Biol Med 2014,71,165-175","journal-title":"Free Radic Biol Med"},{"key":"ref=208","doi-asserted-by":"publisher","first-page":"1620","DOI":"10.1080\/21691401.2016.1276919","volume":"45","author":"Sharma D.","year":"2017","unstructured":"Sharma D.; Singh M.; Kumar P.; Vikram V.; Mishra N.; Development and characterization of morin hydrate loaded microemulsion for the management of Alzheimer\u2019s disease. Artif Cells Nanomed Biotechnol 2017,45(8),1620-1630","journal-title":"Artif Cells Nanomed Biotechnol"},{"key":"ref=209","doi-asserted-by":"publisher","first-page":"370","DOI":"10.1016\/j.ijantimicag.2017.08.025","volume":"51","author":"Rodriguez A.A.M.","year":"2018","unstructured":"Rodriguez A.A.M.; Carvalho L.J.M.; Kimura E.A.; Katzin A.M.; Perillyl alcohol exhibits in vitro inhibitory activity against plasmodium falciparum and protects against experimental cerebral malaria. Int J Antimicrob Agents 2018,51(3),370-377","journal-title":"Int J Antimicrob Agents"},{"key":"ref=210","doi-asserted-by":"publisher","first-page":"17","DOI":"10.3390\/ijms17091463","volume":"17","author":"Chen T.C.","year":"2016","unstructured":"Chen T.C.; Da Fonseca C.O.; Sch\u00f6nthal A.H.; Perillyl alcohol and its drug-conjugated derivatives as potential novel methods of treating brain metastases. Int J Mol Sci 2016,17(9),17","journal-title":"Int J Mol Sci"},{"key":"ref=211","doi-asserted-by":"publisher","first-page":"3544","DOI":"10.1002\/jps.24557","volume":"104","author":"Elnaggar Y.S.R.","year":"2015","unstructured":"Elnaggar Y.S.R.; Etman S.M.; Abdelmonsif D.A.; Abdallah O.Y.; Intranasal piperine-loaded chitosan nanoparticles as brain-targeted therapy in Alzheimer\u2019s disease: optimization, biological efficacy, and potential toxicity. J Pharm Sci 2015,104,3544-3556","journal-title":"J Pharm Sci"},{"key":"ref=212","first-page":"10132","volume":"8","author":"Yang J.A.","year":"2015","unstructured":"Yang J.A.; Li J.Q.; Shao L.M.; Puerarin inhibits proliferation and induces apoptosis in human glioblastoma cell lines. Int J Clin Exp Med 2015,8(6),10132-10142","journal-title":"Int J Clin Exp Med"},{"key":"ref=213","doi-asserted-by":"publisher","first-page":"167","DOI":"10.3390\/nu8030167","volume":"8","author":"Li Y.","year":"2016","unstructured":"Li Y.; Yao J.; Han C.; Quercetin, inflammation and immunity. Nutrients 2016,8(3),167","journal-title":"Nutrients"},{"key":"ref=214","doi-asserted-by":"publisher","first-page":"408","DOI":"10.1016\/j.ejpb.2017.04.009","volume":"117","author":"Hommoss G.","year":"2017","unstructured":"Hommoss G.; Pyo S.M.; M\u00fcller R.H.; Mucoadhesive tetrahydrocannabinol-loaded NLC - Formulation optimization and long-term physicochemical stability. Eur J Pharm Biopharm 2017,117,408-417","journal-title":"Eur J Pharm Biopharm"},{"key":"ref=215","doi-asserted-by":"publisher","first-page":"329","DOI":"10.3109\/03639045.2010.513009","volume":"37","author":"Al-Ghananeem A.M.","year":"2011","unstructured":"Al-Ghananeem A.M.; Malkawi A.H.; Crooks P.A.; Bioavailability of \u0394-tetrahydrocannabinol following intranasal administration of a mucoadhesive gel spray delivery system in conscious rabbits. Drug Dev Ind Pharm 2011,37(3),329-334","journal-title":"Drug Dev Ind Pharm"},{"key":"ref=216","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0129749","volume":"10","author":"G\u00fcnther G.","year":"2015","unstructured":"G\u00fcnther G.; Berr\u00edos E.; Pizarro N.; Flavonoids in microheterogeneous media, relationship between their relative location and their reactivity towards singlet oxygen. PLoS One 2015,10(6)","journal-title":"PLoS One"},{"key":"ref=217","doi-asserted-by":"publisher","first-page":"1319","DOI":"10.1248\/bpb.34.1319","volume":"34","author":"Lu T.","year":"2011","unstructured":"Lu T.; Jiang Y.; Zhou Z.; Intranasal ginsenoside Rb1 targets the brain and ameliorates cerebral ischemia\/reperfusion injury in rats. Biol Pharm Bull 2011,34(8),1319-1324","journal-title":"Biol Pharm Bull"},{"key":"ref=218","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1111\/j.1745-7254.2007.00486.x","volume":"28","author":"Zhao Y.","year":"2007","unstructured":"Zhao Y.; Yue P.; Tao T.; Chen Q.H.; Drug brain distribution following intranasal administration of Huperzine A in situ gel in rats. Acta Pharmacol Sin 2007,28(2),273-278","journal-title":"Acta Pharmacol Sin"},{"key":"ref=219","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1016\/j.ijpharm.2006.12.029","volume":"337","author":"Yue P.","year":"2007","unstructured":"Yue P.; Tao T.; Zhao Y.; Ren J.; Chai X.; Huperzine A in rat plasma and CSF following intranasal administration. Int J Pharm 2007,337(1-2),127-132","journal-title":"Int J Pharm"},{"key":"ref=220","doi-asserted-by":"publisher","first-page":"250","DOI":"10.1016\/j.ejpb.2018.02.010","volume":"127","author":"Trotta V.","year":"2018","unstructured":"Trotta V.; Pavan B.; Ferraro L.; Brain targeting of resveratrol by nasal administration of chitosan-coated lipid microparticles. Eur J Pharm Biopharm 2018,127,250-259","journal-title":"Eur J Pharm Biopharm"},{"key":"ref=221","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1016\/j.jconrel.2017.11.047","volume":"270","author":"Pires P.C.","year":"2018","unstructured":"Pires P.C.; Santos A.O.; Nanosystems in nose-to-brain drug delivery: A review of non-clinical brain targeting studies. J Control Release 2018,270,89-100","journal-title":"J Control Release"},{"key":"ref=222","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1016\/j.jconrel.2018.12.049","volume":"295","author":"Costa C.","year":"2019","unstructured":"Costa C.; Moreira J.N.; Amaral M.H.; Sousa Lobo J.M.; Silva A.C.; Nose-to-brain delivery of lipid-based nanosystems for epileptic seizures and anxiety crisis. J Control Release 2019,295,187-200","journal-title":"J Control Release"},{"key":"ref=223","doi-asserted-by":"publisher","first-page":"369","DOI":"10.1080\/17425247.2018.1429401","volume":"15","author":"Battaglia L.","year":"2018","unstructured":"Battaglia L.; Panciani P.P.; Muntoni E.; Lipid nanoparticles for intranasal administration: application to nose-to-brain delivery. Expert Opin Drug Deliv 2018,15(4),369-378","journal-title":"Expert Opin Drug Deliv"},{"key":"ref=224","doi-asserted-by":"publisher","DOI":"10.1063\/1.5087122","volume":"3","author":"Li X.","year":"2019","unstructured":"Li X.; Corbett A.L.; Taatizadeh E.; Challenges and opportunities in exosome research-perspectives from biology, engineering, and cancer therapy. APL Bioeng 2019,3(1)","journal-title":"APL Bioeng"}],"container-title":["Current Pharmaceutical Design"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/eurekaselect.com\/article\/download\/178321","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,2,22]],"date-time":"2021-02-22T05:40:30Z","timestamp":1613972430000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.eurekaselect.com\/178321\/article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,3,20]]},"references-count":224,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2020,3,20]]}},"alternative-id":["LiveAll1"],"URL":"https:\/\/doi.org\/10.2174\/1381612826666200115101544","relation":{},"ISSN":["1381-6128"],"issn-type":[{"value":"1381-6128","type":"print"}],"subject":[],"published":{"date-parts":[[2020,3,20]]},"assertion":[{"value":"Peer Reviewed","order":0,"name":"review_status","label":"Review Status","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Single blind","order":1,"name":"review_process","label":"Review Process","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Checked with iThenticate","order":0,"name":"screening_status","label":"Screening Status","group":{"name":"plagiarism_screening","label":"Plagiarism Screening"}},{"value":"2019-10-15","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"order":1,"name":"revised","label":"Revised","group":{"name":"publication_history","label":"Publication History"}},{"value":"2019-12-11","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2020-03-20","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}